National Lung Cancer Audit 2009

Prepared in partnership with:

The Healthcare Quality Improvement Partnership (HQIP) promotes quality in healthcare. HQIP holds commissioning and funding responsibility for the National Lung Cancer Audit and other national clinical audits.

The NHS Information Centre for Health and Social Care (The NHS IC) is England's central, authoritative source of essential data and statistical information for frontline decision makers in health and social care. The NHS IC managed the publication of the 2009 annual report.

The Royal College of Physicians of London provides a huge range of services to its 24,000 Members and Fellows and other medical professionals. These include delivering examinations, training courses, continuous professional development and conferences; undertaking clinical audits; publishing newsletters, guidelines and books through to maintaining the College's historical collections. It also leads medical debate, and lobbies and advises government and other decision-makers on behalf of its members.

National Lung Cancer Audit 2009

Report for the audit period 2008

Contents

Acknowledgements

The NLCA project team would like to thank all the organisations that have made this report possible. These include The Royal College of Physicians (The RCP), The Healthcare Quality Improvement Partnership (HQIP), NHS Connecting for Health (CFH), The University of Nottingham, The NHS Information Centre (The IC), The Wales CaNISC (The Cancer Information System Cymru) team, South-East Scotland Cancer Network (SCAN), North of Scotland Cancer Network (NoSCAN) and West of Scotland Cancer Network (WoSCAN). Thanks must also go to all the service users who have contributed data to the audit, without their considerable efforts this report would not be possible.

The NLCA project team have listened to the comments of service users concerning the previous annual reports, and as a result have produced this short report highlighting key issues. The team plan to publish more extensive analyses on the 2008 data, including case mix-adjusted data in an electronic format that can be more easily used by trusts. These data will be presented in a tabular format with minimal accompanying text, and will be available from the IC website in due course.

Purpose of this report

The purpose of this document is to summarise the key finding of the National Lung Cancer Audit for patients diagnosed with lung cancer or mesothelioma who were first seen in 2008. Every trust in England and Wales, and every Health Board in Scotland has participated in the audit at some stage since its initiation. Only 3 English trusts and 2 Scottish island Health Boards did not participate in the current audit period.

The Scottish lung cancer dataset (excluding mesothelioma) has been collected for a number of years and this is the second year that the three Scottish networks have contributed data to the NLCA. Because of differences in reporting schedules, standards and targets the Scottish data are tabulated separately.

All data presented refers to cases submitted to the National Lung Cancer Audit unless otherwise stated.

Key messages

- The audit has collected data on 32,447 patients in Great Britain for this audit period, representing over 85 per cent of the expected number of lung cancer cases. This represents approximately 94 per cent of cases presenting to secondary care (compared to the 'expected number' of cases per trust, derived from historic cancer registry data and agreed with individual organisations). By the end of June 2008, all cancer networks in England, Wales and Scotland were contributing to the audit.
- The quality of the submitted data has improved compared with previous years allowing more detailed comparison of cancer networks and hospital trusts. Overall the measures of care appear to be improving slowly but still are below those reported from other Western European countries.
- Despite these improvements, there remains wide variation across trusts and networks and differences in casemix do not appear to explain the whole of this variation. Poor data completeness in a few areas, especially where trusts fall at the lower extreme of these measures, may contribute to the variation seen:–

    1. For England and Wales, histological confirmation (i.e. a diagnosis made by taking a sample of tissue or cells) of the cancer diagnosis is made in 72 per cent with wide variation from 25 per cent to more than 85 per cent. Whilst this is an improvement on the 68 per cent achieved last year it is still below the 75 per cent target which is considered a reasonable benchmark for acceptable practice. A target of 100 per cent is not appropriate because there will always be a proportion of patients who are unfit for a biopsy procedure because of poor performance status or severe co-morbidity. Cancer Networks and Hospital Trusts need to review their diagnostic policies and ensure they have access to the full range of tissue sampling techniques. For Scotland this figure is 77.5 per cent (range 56 per cent to 88 per cent) which is an increase of 1.5 per cent compared to last year.

    2. The overall unadjusted proportion of lung cancer patients in England and Wales receiving an operation to try to cure their cancer is approximately 11 per cent but varies from less than 5 per cent to more than 25 per cent. (Range up to 17 per cent in Scotland). Organisations need to review their pathways for decisions on, and referral for lung cancer surgery, for example by increasing access to specialist thoracic surgeons at multidisciplinary team meetings (MDTs).

    3. Active anti-cancer treatment (i.e. surgery, chemotherapy or radiotherapy) is offered to 54 per cent of patients in England and Wales, which is an increase of 3 per cent compared to last year. The figure varies between trusts from less than 10 per cent to more than 80 per cent. Cancer Networks and Hospital Trusts need to examine their processes for decisions on, and referral for cancer treatment, for example by reviewing their local treatment policies in light of national guidance. In Scotland 64 per cent of patients receive active anti cancer treatment (range 33 – 79.5 per cent) which is a 2 per cent increase compared to last year.

    4. Audit data for England and Wales suggest that in many cases, national guidance is not being followed. For example only 76 per cent of patients have a CT scan prior to bronchoscopy and only 48 per cent of patients with advanced non-small cell lung cancer who are of good performance status receive chemotherapy. Other measures of good practice such as the proportion of patients seeing lung cancer specialist nurses (51 per cent) and the proportion of patients with small cell lung cancer receiving chemotherapy (62 per cent) are unacceptably low. Cancer Networks and Hospital Trusts with results below each national mean should review their operational policies to come into line with best practice.

- Although there is evidence that the audit data is being used in some organisations to help bring about service improvement, there remains an urgent need for all Cancer Networks and Hospital Trusts to take responsibility for their data and use it to review their local lung cancer services. This report contains a toolkit to help with this process.

Recommendations (England and Wales)

- All trusts should ensure that they participate in this national audit
- Data on all patients diagnosed with either lung cancer or mesothelioma are submitted to the audit
- All relevant data fields are completed for each patient
- Actual completeness of at least 80 per cent should be achieved for key data fields including stage and performance status, and completeness of 95 per cent should be achieved for MDT
- Over 95 per cent of patients submitted to the audit are discussed at a Multidisciplinary Team Meeting
- The Histological/Cytological Confirmation Rate is at least 75 per cent
- Over 80 per cent of patients are seen by a lung cancer specialist nurse
- Over 80 per cent of patients have a lung cancer specialist nurse present at the time of diagnosis
- Surgical resection rates below the national mean of 11 per cent should be reviewed
- Active anti-cancer treatment rates below the national mean of 54 per cent should be reviewed
- Chemotherapy rates for small cell lung cancer below the national mean of 62 per cent should be reviewed
- Chemotherapy rates for performance status 0–1 stage IIIB / IV NSCLC lung cancer below the national mean of 48 per cent should be reviewed
- Where CT scan prior to bronchoscopy rates are lower than 90 per cent, the results should be reviewed.
- Trusts who have exceeded these targets in 2008 should work to maintain their high standards and exceed them where appropriate

A local action planning toolkit is provided at the end of this document to assist organisations in benchmarking against these quality measures. All organisations are encouraged to use the audit data to drive their service development in order to improve the standard of care for lung cancer patients.

Performance against these targets is highlighted by a system of colour-coding in the data tables. However these targets do not apply to Scotland and hence these data are not colour coded. NHS Quality Improvement Scotland published National Lung Cancer Standards in March 2008 which cover similar items to those noted above. For example, the Scottish standard for rate of histological / cytological diagnosis is set at a minimum of 75 per cent. Health boards in all Scottish networks will participate in comparing 2008 results measured against these standards.

The Scottish Strategy "Better Cancer Care" published by the Scottish Government in October 2008 contains the commitment that it will "Ensure by 2010, all tumour networks take part in national audit...".

Wales will need to consider the proposed recommendations and actions as part of its national cancer strategy, along with advice from its clinical lung cancer advisors.

Summary details of key findings

How many people were diagnosed with lung cancer?

In 2008 there were 28,389 patient records submitted from England and Wales (see Figure 1) and 4058 submitted from Scotland that were analysed separately (see Figure 2). Combined, this is approximately 85 per cent of the annual incidence and 94 per cent of those presenting to secondary care. 575 of these records were not suitable for further analysis (all of which came from English submissions) as there was no "date first seen" recorded, meaning that it was not possible to be certain that these were cases from 2008. Figure 1 and 2 show the incidence by cancer type.

There has been a year on year increase in submissions from a baseline of 12,784 (40 per cent of expected – originally England only) in 2005 as shown in figure 3:

In Scotland overall case ascertainment has risen slightly from 88 per cent last year to 89 per cent for this cohort.

Figure 1
Number of patient records submitted to the NLCA – England and Wales



Figure 2
Number of patient records submitted to the NLCA – Scotland



How accurate are the data in this report?

Data submitted to the National Lung Cancer Audit needs to be as complete as possible in terms of organisation, sample size and data fields both to ensure the representative nature of the population and to make case-mix adjustment possible. Please refer to previous versions of the Annual Report for a full explanation of this issue.

All Networks in England, Wales and Scotland have participated in the audit,169 of 172 eligible trusts (98.2 per cent) in England and Wales have participated by uploading data on patients first seen in 2008 and all Scottish Health Boards have participated in the audit (however 2 island health boards have not contributed data this year).
The following English trusts did not participate in the NLCA in 2008, although there may still be data on patients first seen at these trusts by virtue of data being submitted by treating trusts.

- Maidstone and Tunbridge Wells NHS Trust (RWF) (N34 Kent and Medway Cancer Network)
- Shrewsbury and Telford Hospital NHS Trust (RXW) (N35 Greater Midland Cancer Network)
- Ipswich Hospital NHS Trust (RGQ) (N37 Anglia Cancer Network)

As can be seen from Figures 1 and 2, nationally the audit has captured approximately 85 per cent of the expected number of cases and 94 per cent of those presenting to secondary care. The "Data Completeness" section in Table 1a shows the number of cases and per cent of expected cases (based on historic cancer registry returns) submitted by Network and by Trust (key to codes given in the Appendix 1) across England and Wales. Table 1b shows similar data for Scottish networks. Similarly these tables indicate the data completeness for the key non-mandatory fields of Stage and Performance Status (PS) and the data completeness for the MDT discussion indicator and for the recording of treatment. Comparison with previous years (figure 4 England and Wales) shows that data field completeness continues to improve. In Scotland, the generally high levels of data completeness for MDT discussion indicator (95 per cent+) show an 8 per cent drop in overall result because of recording problems experienced in one health board when there was a change of database. The actual number of patients discussed in that health board is unlikely to have changed significantly from the 100 per cent recorded in the previous year.

Figure 3
Case ascertainment by year

* England only ** England and Wales



Figure 4
Key data field completeness by year

PS Stage * England only ** England and Wales



What is the standard of care given to patients?

Table 2a, Process, Specialist Nursing, Imaging and Outcome: – England and Wales lists headline indicators by Network and by Trust (key to codes given in the Appendix 1) for all lung cancer and mesothelioma across England and Wales. These indicators have been chosen to reflect the overall standard of care provided to patients. In interpreting these figures, the caveats discussed previously regarding data completeness must be borne in mind. Furthermore, the results as presented do not take into account the case-mix of patients. Adjustments to the results to account for case-mix will be available from the IC website in due course, although it is to be noted that this adjustment does not in general make significant differences to the relative performance of organisations.

The colour coding reflects the targets set in the 2007 Local Action Plan and gives an overall picture of how a trust or network is performing against these targets. Note that for case ascertainment (per cent of expected), to achieve green status over 75 per cent of the expected number of cases must have been submitted, trusts attaining 50 – 75 percent are coded amber whilst trusts submitting less that 50 per cent of the expected number are coded red. Trusts with a high tertiary workload or where the targets are known to not be applicable for other reasons are shown in blue throughout. Many of the trusts in this category fully participate in the audit by submitting treatment data for other trusts. However their full contribution to the audit process may not be reflected by the way these audit data are presented.

Similar data for Scotland is shown in table 2b. LAP targets do not apply to Scotland; hence the data are not colour coded. National Lung Cancer Standards published by NHS Quality Improvements Scotland in 2008 include standards for rate of histological confirmation (minimum 75 per cent) and percentage SCLC having chemotherapy (minimum 60 per cent) but do not specify rates of resection or anti-cancer treatment.

Converting data in to service improvement

Collecting data is only part of the audit process and it is important that these data are used to improve the services provided to patients and the outcomes of their treatment. There are numerous examples of local organisations doing just this and an example is given below. Furthermore, national organisations such as the National Institute for Health and Clinical Excellence, the British Thoracic Society and the National Cancer Peer Review Programme have all utilised data from the audit in their work programmes for lung cancer.

Case study 1 North Tees and Hartlepool NHS Trust

In 2008 the second LUCADA report was published covering the audit period 2006. In response to this, North Tees and Hartlepool NHS Foundation Trust, with Cancer Manager support, implemented a programme to improve key areas. The functioning of the MDT and the availability of reliable data were important issues identified as key to improving the quality of care. Steps were taken to ensure that all relevant patients were discussed at the MDT. The length of the MDT meeting was increased to allow more time for discussion and data collection, and the meeting moved to within normal hours to facilitate attendance. Led by the lead clinician and MDT co-ordinator with the help of all team members, increased effort was made to record more complete data on all patients. As a result of these efforts data for key fields is now completed for approximately 95 per cent of patients compared with approximately 60-65 per cent previously. Effort was also invested in improving the histological confirmation rate.

The hard work of North Tees and Hartlepool NHS Foundation has been worthwhile. The improved functioning of the MDT and more complete data collection have facilitated audits on surgical resection, small cell chemotherapy, histological confirmation rate and missed MDT discussion. During the same time frame new additional oncology and surgery appointments have occurred and all of these factors are reflected in current NLCA figures with reported surgical resection rate for all cancers increased from 8 per cent (2006) to 13 per cent in 2008 and small cell chemotherapy increased from 55 per cent (2006) to 66.7 per cent in 2008.

Importance of the lung cancer nurse specialist

Data from the national lung cancer audit shows that patients seen by a lung cancer nurse specialist (LCNS) were more likely to receive active treatment compared to those that were not seen or those where no data is recorded and hence it is not known whether these patients saw a LCNS.

The table shows that 59 per cent of patients seen by an LCNS received active treatment, compared to only 30 per cent of those who were not seen by the LCNS. For patients where it was not known whether or not they were seen by the LCNS 51 per cent received active treatment.

Whilst this is an interesting finding that highlights the importance of the role of the LCNS, further work is needed to explain this observation, especially as data was not recorded for over half of the cases reported.

Proportion of patients seen by a LCNS receiving active treatment	
Seen by LCNS	59.4%
Data not recorded	51.0%
Not seen by LCNS	30.6%

Trust performance

Handling of low case numbers

It should be noted that trusts submitting very low numbers of cases with high levels of data completeness have been omitted from the tables below to ensure that no details about specific patients can be identified in this report. Because of this network totals may not equal the sum of the composite trusts. For example, in a trust with only two submitted cases of lung cancer, with 100 per cent data completeness and a resection rate of 100 per cent, it would be possible to know the details of treatment of all lung cancer patients seen at that trust. However in most cases, each reported value is composed of multiple variables so it is impossible to surmise information about specific individuals from this report.

Data groupings

England and Wales

For England and Wales the data has been divided into 4 groups for analysis:–

- All cases of lung cancer submitted to the audit (this includes lung cancer and mesothelioma). This is the default grouping on which all analyses have been carried out unless otherwise specified.
- NSCLC – non-small cell lung cancer or perhaps, more correctly, this should be considered NOT small cell lung cancer. This group includes all lung cancers including those that are clinically diagnosed, but excludes diagnoses of small cell lung cancer and mesothelioma.
- Histologically-confirmed non-small cell lung cancer – As the name suggests, all cases of non-small cell lung cancer that are confirmed by a histological or cytological diagnosis.
- Small cell lung cancer – Again as the name suggests, all cases of small cell lung cancer that are confirmed by a histological or cytological diagnosis.

Scotland

For the analyses in Scotland the groupings are slightly different as mesothelioma cases are not included in the current audit data (Collection of Mesothelioma data is Scotland is due to start in January 2010). The two groupings used were:–

- All Cases of lung cancer submitted to the audit. (This includes lung cancer but excludes mesothelioma) This is the default grouping on which all Scottish analyses have been carried out unless otherwise specified.
- Small cell lung cancer – All cases of small cell lung cancer that are confirmed by a histological or cytological diagnosis.

Table 1a
Data completeness for key fields England and Wales

Code	Expected number	Actual Number	% of expected	MDT Completeness (%)	Performance Status Completeness (%)	Stage Completeness (%)	PS & Stage Completeness (%)	Treatment Recorded (%)	Data Completeness Seen by Nurse Specialist (%)	Data Completeness Nurse Specialist present at diagnosis (%)	CT Scan Field Completed (%)	Bronchoscopy Field Completed (%)
N01	**989**	**993**	**100**	**97.7**	**43.9**	**80.9**	**41.3**	**90.2**	**45.7**	**43.5**	**99.6**	**99.2**
RTX	184	222	121	97.7	14.4	57.2	11.3	80.2	11.7	11.7	99.5	99.1
RXL	242	228	94	100.0	91.2	99.1	90.8	94.7	99.1	89.9	100.0	99.1
RXN	136	242	178	97.5	48.3	97.1	47.9	89.3	80.2	79.8	100.0	100.0
RXR	427	301	70	96.0	26.2	71.4	20.6	95.0	2.7	2.7	99.0	98.7
N02	**2,134**	**1597**	**75**	**51.7**	**60.2**	**65.7**	**45.4**	**54.4**	**62.5**	**28.5**	**79.1**	**78.4**
RBT	116	16	14	0.6	6.3	43.8	0.0	62.5	0.0	0.0	12.5	6.3
RBV	165	0	0									
RJN	89	53	60	52.8	84.9	71.7	67.9	60.4	84.9	28.3	96.2	77.4
RM2	321	75	23	13.3	1.3	42.7	0.0	81.3	2.7	2.7	29.3	28.0
RM3	135	178	132	68.5	56.2	73.0	43.8	66.9	64.0	37.6	93.8	47.8
RM4	89	83	93	65.1	98.8	89.2	88.0	62.7	100.0	84.3	98.8	98.8
RMC	196	194	99	57.2	93.3	75.8	70.1	66.5	73.2	30.9	7.7	100.0
RMP	130	135	104	45.9	74.8	74.8	59.3	97.8	85.2	53.3	100.0	100.0
RRF	161	302	188	68.9	82.5	61.3	57.0	24.2	92.7	1.0	98.0	56.6
RW3	103	113	110	51.3	88.5	64.6	54.9	85.0	85.0	57.5	98.2	100.0
RW6	524	313	60	38.0	1.3	46.6	1.0	31.0	3.8	3.5	82.4	98.1
RWJ	105	135	129	40.0	71.9	86.7	63.0	50.4	80.7	66.7	92.6	75.6

Table 1a (continued)
Data completeness for key fields England and Wales

Code	Expected number	Actual Number	% of expected	MDT Completeness (%)	Performance Status Completeness (%)	Stage Completeness (%)	PS & Stage Completeness (%)	Treatment Recorded (%)	Data Completeness Seen by Nurse Specialist (%)	Data Completeness Nurse Specialist present at diagnosis (%)	CT Scan Field Completed (%)	Bronchoscopy Field Completed (%)
N03	**1,535**	**1405**	**92**	**96.4**	**65.9**	**65.6**	**50.2**	**63.5**	**47.1**	**27.8**	**82.8**	**72.1**
RBL	119	221	186	88.2	5.0	39.8	4.1	49.3	91.4	1.4	89.1	78.3
RBN	221	161	73	97.5	67.7	80.7	55.9	93.2	71.4	64.0	100.0	100.0
RBQ	212	195	92	98.5	88.7	83.6	74.9	74.9	0.0	0.0	97.9	97.9
REM	323	163	50	80.4	50.9	41.7	27.0	52.1	30.1	19.6	92.0	20.9
REN	48	0										
RJR	121	188	155	100.0	100.0	96.3	96.3	41.0	0.0	0.0	0.0	0.0
RQ6	216	123	57	96.7	82.1	71.5	59.3	61.8	0.0	0.0	94.3	94.3
RVY	82	141	172	99.3	75.2	61.0	52.5	97.9	88.7	88.7	100.0	100.0
RWW	193	213	110	94.4	72.8	55.4	41.3	52.1	80.3	59.6	97.7	92.5
N06	**1811**	**1669**	**92**	**97.9**	**77.6**	**65.5**	**56.1**	**89.0**	**70.5**	**25.1**	**95.3**	**60.9**
RAE	240	209	87	99.5	96.7	94.3	91.4	93.3	99.5	75.6	99.0	98.6
RCB	173	140	81	97.1	95.0	72.9	70.0	94.3	100.0	13.6	100.0	100.0
RCD	91	94	103	95.7	85.1	95.7	84.0	80.9	98.9	94.7	96.8	61.7
RCF	118	74	63	100.0	78.4	73.0	56.8	100.0	41.9	0.0	93.2	13.5
RR8	565	463	82	99.8	79.9	77.7	64.5	88.1	99.6	0.4	99.6	22.3
RWY	244	249	102	97.2	49.8	58.6	35.3	98.4	83.9	51.4	97.2	57.0
RXF	380	440	116	95.9	74.5	33.0	31.8	80.7	8.0	5.2	86.4	80.9
N07	**753**	**572**	**76**	**98.4**	**92.1**	**84.1**	**79.9**	**95.3**	**54.5**	**31.6**	**96.7**	**98.4**
RCC	126	15	12	73.3	73.3	73.3	60.0	73.3	60.0	53.3	73.3	73.3
RJL	226	189	84	97.4	79.9	82.0	71.4	94.7	43.9	27.0	98.4	97.9
RWA	401	368	92	100.0	99.2	85.6	85.1	96.5	59.8	33.2	96.7	99.7
N08	**1246**	**1146**	**92**	**107.8**	**87.2**	**89.0**	**79.3**	**85.4**	**13.9**	**10.0**	**94.5**	**88.4**
RFF	131	119	91	199.0	89.1	86.6	78.2	62.2	1.7	1.7	47.1	46.2
RFR	144	135	94	100.0	99.3	88.1	88.1	93.3	81.5	63.7	100.0	100.0
RFS	174	185	106	100.0	95.7	75.7	71.4	98.9	34.1	20.5	100.0	100.0
RHQ	480	483	101	99.8	100.0	99.4	99.4	94.8	0.2	0.0	99.6	99.4
RP5	317	343	108	94.8	59.2	82.8	52.2	69.7	0.0	0.0	98.5	76.7
N11	**1066**	**1056**	**99**	**97.2**	**81.8**	**88.8**	**74.9**	**89.2**	**73.8**	**53.0**	**97.3**	**85.5**
RBK	158	174	110	97.7	97.1	93.1	92.0	90.8	98.9	76.4	98.9	98.9
RR1	404	382	95	94.2	82.5	85.9	73.6	82.5	70.7	63.4	95.8	83.8
RRK	245	225	92	100.0	97.3	99.6	96.9	91.6	97.3	81.3	100.0	100.0
RXK	259	273	105	99.3	59.0	81.3	48.4	95.6	43.2	0.7	96.7	67.8
N12	**414**	**467**	**113**	**93.8**	**54.8**	**60.2**	**40.3**	**77.1**	**58.9**	**45.8**	**79.4**	**76.4**
RJC	5	47	940	40.4	29.8	51.1	6.4	46.8	34.0	29.8	40.4	31.9
RKB	249	237	95	99.6	62.4	52.3	46.0	78.9	78.9	66.2	99.6	99.6
RLT	96	115	120	100.0	67.0	81.7	55.7	86.1	7.0	0.9	42.6	33.9
RWP01	64	68	106	100.0	25.0	57.4	17.6	76.5	94.1	61.8	98.5	98.5
N13	**851**	**870**	**102**	**99.1**	**66.6**	**79.7**	**60.2**	**97.5**	**27.1**	**25.6**	**82.8**	**79.0**
RK5	170	216	127	98.2	96.8	95.4	92.6	98.1	100.0	99.5	100.0	100.0
RWD	349	298	85	98.7	16.8	59.4	15.1	94.0	6.7	2.7	79.9	80.2
RX1	332	356	107	100.0	89.9	87.1	78.4	100.0	0.0	0.0	74.7	65.2
N14	**319**	**451**	**141**	**98.5**	**71.6**	**67.4**	**56.3**	**90.0**	**69.6**	**56.5**	**91.4**	**13.7**
RJF	62	128	206	96.1	86.7	97.7	85.2	92.2	99.2	72.7	98.4	44.5
RTG	257	323	126	99.4	65.6	55.4	44.9	89.2	57.9	50.2	88.5	1.5

Table 1a (continued)
Data completeness for key fields England and Wales

Code	Expected number	Actual Number	% of expected	MDT Completeness (%)	Performance Status Completeness (%)	Stage Completeness (%)	PS & Stage Completeness (%)	Treatment Recorded (%)	Data Completeness Seen by Nurse Specialist (%)	Data Completeness Nurse Specialist present at diagnosis (%)	CT Scan Field Completed (%)	Bronchoscopy Field Completed (%)
N15	**753**	**813**	**108**	**98.2**	**78.6**	**81.5**	**67.0**	**83.5**	**26.0**	**17.7**	**81.8**	**34.6**
RNQ	146	179	123	96.1	74.9	78.8	67.6	59.8	41.9	41.9	23.5	7.3
RNS	142	141	99	94.3	81.6	73.8	63.8	97.2	81.6	48.2	97.2	92.2
RWE	465	492	106	100.0	79.1	85.0	67.9	88.2	4.3	0.2	98.6	28.0
N20	**532**	**540**	**102**	**99.4**	**72.0**	**52.8**	**48.1**	**88.9**	**53.3**	**40.7**	**74.6**	**64.8**
RC9	109	141	129	100.0	82.3	66.0	58.9	75.2	53.2	17.7	97.2	59.6
RWG	217	126	58	97.6	48.4	40.5	35.7	88.9	0.0	0.0	0.0	0.0
RWH	206	273	133	100.0	77.7	51.6	48.4	96.0	78.0	71.4	97.4	97.4
N21	**806**	**471**	**58**	**97.9**	**79.6**	**76.2**	**64.1**	**80.3**	**79.2**	**59.0**	**83.0**	**62.4**
RAS	105	102	97	100.0	99.0	64.7	63.7	100.0	99.0	99.0	98.0	28.4
RC3	55	58	105	98.3	91.4	70.7	69.0	86.2	100.0	75.9	96.6	58.6
RFW	55	69	125	100.0	100.0	100.0	100.0	88.4	100.0	0.0	100.0	100.0
RQM	53	52	98	98.1	96.2	96.2	92.3	13.5	1.9	0.0	1.9	1.9
RT3	148	7	5	100.0	85.7	71.4	71.4	100.0	0.0	0.0	0.0	0.0
RV8	154	40	26	80.0	35.0	50.0	20.0	70.0	60.0	50.0	90.0	77.5
RYJ	236	142	60	100.0	57.0	75.4	46.5	85.9	83.8	78.9	90.1	90.8
N22	**732**	**620**	**85**	**89.8**	**87.6**	**86.8**	**81.9**	**81.1**	**76.6**	**66.9**	**78.9**	**73.5**
RAL	86	93	108	98.8	96.8	97.8	94.6	95.7	100.0	97.8	100.0	73.1
RAP	84	71	85	94.4	94.4	90.1	85.9	81.7	95.8	93.0	97.2	97.2
RKE	98	80	82	95.0	81.3	95.0	78.8	92.5	95.0	80.0	95.0	87.5
RQW	113	78	69	50.0	47.4	47.4	43.6	44.9	42.3	34.6	52.6	51.3
RRV	139	86	62	98.8	100.0	100.0	100.0	100.0	1.2	0.0	1.2	1.2
RVL	212	212	100	93.4	93.4	86.8	83.0	75.9	96.2	78.8	98.6	98.1
N23	**780**	**600**	**77**	**75.3**	**47.3**	**59.7**	**39.8**	**81.5**	**78.0**	**45.5**	**75.3**	**75.7**
RF4	340	179	53	74.3	12.8	49.2	6.7	92.7	57.5	10.1	69.8	74.9
RGC	115	135	117	94.8	68.9	85.2	63.7	82.2	94.8	84.4	94.8	94.1
RNH	115	105	91	92.4	83.8	76.2	70.5	78.1	84.8	58.1	93.3	99.0
RNJ	110	75	68	8.0	5.3	1.3	1.3	89.3	74.7	1.3	6.7	9.3
RQX	100	104	104	83.7	72.1	70.2	62.5	59.6	86.5	75.0	91.3	77.9
N24	**873**	**726**	**83**	**93.9**	**74.9**	**74.1**	**66.8**	**68.3**	**67.2**	**45.6**	**86.8**	**47.8**
RG2	140	171	122	96.5	83.6	86.0	74.9	84.2	76.6	73.7	92.4	41.5
RG3	126	151	120	99.3	98.7	91.4	90.7	80.8	35.8	33.1	98.7	98.0
RGZ	104	78	75	65.4	6.4	2.6	1.3	7.7	78.2	62.8	56.4	19.2
RJ1**	273	115	42	96.5	71.3	83.5	64.3	96.5	92.2	90.4	94.8	93.9
RJ2	116	75	65	92.0	38.7	32.0	18.7	58.7	0.0	0.0	45.3	4.0
RJZ	114	136	119	100.0	100.0	96.3	96.3	50.7	100.0	1.5	100.0	1.5
N25	**785**	**466**	**59**	**40.5**	**19.1**	**55.8**	**15.2**	**55.6**	**20.0**	**8.6**	**79.4**	**40.1**
5LG	10	2	20	0.0	0.0	0.0	0.0	50.0	0.0	0.0	100.0	0.0
RAX	159	106	67	28.3	0.9	67.9	0.9	50.9	6.6	6.6	79.2	37.7
RJ6	132	113	86	57.5	45.1	64.6	31.0	49.6	0.0	0.0	77.0	32.7
RJ7	239	101	42	88.1	36.6	78.2	34.7	98.0	84.2	32.7	72.3	36.6
RPY	0	0										
RVR	245	143	58	3.5	0.0	25.2	0.0	33.6	0.0	0.0	86.7	51.0

Table 1a (continued)
Data completeness for key fields England and Wales

Code	Expected number	Actual Number	% of expected	MDT Completeness (%)	Performance Status Completeness (%)	Stage Completeness (%)	PS & Stage Completeness (%)	Treatment Recorded (%)	Data Completeness Seen by Nurse Specialist (%)	Data Completeness Nurse Specialist present at diagnosis (%)	CT Scan Field Completed (%)	Bronchoscopy Field Completed (%)
N26	**920**	**1105**	**120** ●	**94.6** ▲	**67.8** ▲	**88.5** ●	**60.2** ▲	**89.4** ●	**46.8** ▲	**41.2** ▲	**99.5** ●	**99.7** ●
RA9	156	198	127 ●	93.9 ▲	99.0 ●	100.0 ●	99.0 ●	94.9 ●	100.0 ●	86.4 ●	100.0 ●	100.0 ●
RBZ	85	87	102 ●	97.7 ●	69.0 ▲	97.7 ●	67.8 ▲	92.0 ●	92.0 ●	92.0 ●	98.9 ●	98.9 ●
REF	223	284	127 ●	99.6 ●	77.1 ●	61.3 ▲	51.1 ▲	84.2 ●	8.1 ▲	8.1 ▲	100.0 ●	100.0 ●
RH8	200	207	104 ●	99.0 ●	94.7 ●	95.2 ●	90.3 ●	95.7 ●	96.6 ●	79.7 ●	98.1 ●	99.0 ●
RK9	256	328	128 ●	87.2 ▲	23.5 ▲	98.5 ●	23.5 ▲	86.0 ●	4.6 ▲	4.6 ▲	100.0 ●	100.0 ●
N27	**402**	**425**	**106** ●	**98.8** ●	**86.8** ●	**68.9** ▲	**63.1** ▲	**90.4** ●	**34.8** ▲	**28.9** ▲	**56.7** ▲	**49.2** ▲
RBD	82	104	127 ●	99.0 ●	64.4 ▲	69.2 ▲	52.9 ▲	98.1 ●	99.0 ●	86.5 ●	96.2 ●	93.3 ●
RD3	150	127	85 ●	96.9 ●	96.1 ●	69.3 ▲	69.3 ▲	89.0 ●	33.1 ▲	25.2 ▲	94.5 ●	74.8 ▲
RDZ	170	194	114 ●	100.0 ●	92.8 ●	68.6 ▲	64.4 ▲	87.1 ●	1.5 ▲	0.5 ▲	10.8 ▲	8.8 ▲
N28	**844**	**792**	**94** ●	**97.6** ●	**32.2** ▲	**94.8** ●	**31.3** ▲	**85.4** ●	**76.1** ●	**76.1** ●	**99.9** ●	**99.9** ●
RA3	82	77	94 ●	94.8 ▲	42.9 ▲	93.5 ●	36.4 ▲	90.9 ●	77.9 ●	77.9 ●	100.0 ●	100.0 ●
RA4	62	69	111 ●	94.2 ▲	18.8 ▲	95.7 ●	17.4 ▲	82.6 ●	36.2 ▲	36.2 ▲	100.0 ●	100.0 ●
RA7	180	107	59 ■	98.1 ●	2.8 ▲	89.7 ●	2.8 ▲	86.0 ●	88.8 ●	88.8 ●	99.1 ●	99.1 ●
RBA	121	175	145 ●	98.9 ●	97.1 ●	99.4 ●	96.6 ●	85.1 ●	79.4 ●	79.4 ●	100.0 ●	100.0 ●
RD1	170	151	89 ●	98.7 ●	0.0 ▲	98.0 ●	0.0 ▲	92.7 ●	86.8 ●	86.8 ●	100.0 ●	100.0 ●
RVJ	228	213	93 ●	97.7 ●	16.9 ▲	91.5 ●	16.9 ▲	78.9 ●	71.8 ▲	71.8 ▲	100.0 ●	100.0 ●
N29	**437**	**454**	**104** ●	**96.2** ●	**79.1** ●	**86.1** ●	**71.1** ▲	**85.0** ●	**72.9** ▲	**40.3** ▲	**94.3** ●	**97.6** ●
RLQ	74	119	161 ●	100.0 ●	94.1 ●	91.6 ●	87.4 ●	82.4 ●	99.2 ●	68.9 ▲	100.0 ●	100.0 ●
RTE	244	282	116 ●	98.2 ●	75.2 ●	84.4 ●	66.3 ▲	87.6 ●	74.5 ▲	35.5 ▲	94.0 ●	98.9 ●
RWP50	119	53	45 ▲	77.4 ▲	66.0 ▲	83.0 ●	60.4 ▲	77.4 ●	5.7 ▲	1.9 ▲	83.0 ●	84.9 ●
N30	**1031**	**1137**	**110** ●	**96.5** ●	**67.2** ▲	**72.5** ▲	**54.5** ▲	**81.2** ●	**20.8** ▲	**19.1** ▲	**44.1** ▲	**38.9** ▲
RD7	112	156	139 ●	98.7 ●	38.5 ▲	9.6 ▲	9.6 ▲	61.5 ▲	0.0 ▲	0.0 ▲	9.6 ▲	1.9 ▲
RD8	96	79	82 ●	73.4 ▲	55.7 ▲	72.2 ▲	55.7 ▲	86.1 ●	36.7 ▲	36.7 ▲	57.0 ▲	58.2 ▲
RHW	206	170	83 ●	100.0 ●	97.6 ●	90.0 ●	88.8 ●	87.1 ●	91.8 ●	81.2 ●	91.2 ●	84.1 ●
RN3	113	178	158 ●	99.4 ●	12.9 ▲	96.6 ●	11.8 ▲	96.1 ●	21.9 ▲	21.9 ▲	100.0 ●	100.0 ●
RTH	303	353	117 ●	97.4 ●	84.4 ●	76.5 ●	71.1 ▲	70.5 ▲	2.8 ▲	2.5 ▲	22.4 ▲	12.2 ▲
RXQ	201	201	100 ●	97.0 ●	86.1 ●	78.1 ●	68.7 ▲	95.0 ●	1.0 ▲	1.0 ▲	14.4 ▲	14.4 ▲
N31	**1,092**	**958**	**88** ●	**95.8** ●	**54.3** ▲	**83.0** ●	**48.9** ▲	**89.4** ●	**39.9** ▲	**30.7** ▲	**71.3** ▲	**67.8** ▲
RR2/5QT	53	102	192 ●	99.0 ●	91.2 ●	86.3 ●	80.4 ●	88.2 ●	99.0 ●	96.1 ●	100.0 ●	97.1 ●
RHM	448	265	59 ■	90.9 ▲	58.9 ▲	80.4 ●	51.7 ▲	92.1 ●	4.9 ▲	4.2 ▲	97.4 ●	95.1 ●
RHU	279	249	89 ●	97.2 ●	0.0 ▲	88.0 ●	0.0 ▲	90.4 ●	0.0 ▲	0.0 ▲	2.4 ▲	2.4 ▲
RN1	94	44	47 ▲	88.6 ▲	11.4 ▲	6.8 ▲	2.3 ▲	75.0 ●	0.0 ▲	0.0 ▲	45.5 ▲	25.0 ▲
RN5	39	59	151 ●	96.6 ●	61.0 ▲	86.4 ●	52.5 ▲	100.0 ●	83.1 ●	59.3 ▲	100.0 ●	98.3 ●
RNZ	71	98	138 ●	100.0 ●	95.9 ●	91.8 ●	90.8 ●	90.8 ●	83.7 ●	67.3 ▲	99.0 ●	93.9 ●
RPR/RYR	108	141	131 ●	99.2 ●	96.5 ●	92.9 ●	90.8 ●	82.3 ●	97.2 ●	59.6 ▲	100.0 ●	93.6 ●
N32	**540**	**414**	**77** ●	**79.7** ▲	**31.6** ▲	**76.1** ●	**28.7** ▲	**87.0** ●	**68.1** ▲	**62.1** ▲	**82.1** ●	**80.4** ●
RA2	109	56	51 ■	71.4 ▲	3.6 ▲	76.8 ●	3.6 ▲	78.6 ●	66.1 ▲	66.1 ▲	98.2 ●	98.2 ●
RDU	116	143	123 ●	90.2 ▲	36.4 ▲	97.2 ●	35.7 ▲	95.8 ●	79.7 ●	79.7 ●	99.3 ●	99.3 ●
RTK	159	111	70 ■	73.0 ▲	52.3 ▲	89.2 ●	52.3 ▲	100.0 ●	76.6 ●	54.1 ▲	35.1 ▲	28.8 ▲
RTP	156	104	67 ■	76.9 ▲	18.3 ▲	32.7 ▲	7.7 ▲	65.4 ▲	44.2 ▲	44.2 ▲	100.0 ●	100.0 ●
N33	**620**	**583**	**94** ●	**98.8** ●	**54.9** ▲	**92.1** ●	**54.5** ▲	**84.6** ●	**63.6** ▲	**63.1** ▲	**99.1** ●	**99.1** ●
RPL	140	125	89 ●	96.0 ●	56.8 ▲	94.4 ●	56.8 ▲	94.4 ●	69.6 ▲	67.2 ▲	99.2 ●	99.2 ●
RXC	229	242	106 ●	100.0 ●	55.4 ▲	86.8 ●	55.4 ▲	95.5 ●	90.5 ●	90.5 ●	100.0 ●	100.0 ●
RXH	251	215	86 ●	99.1 ●	53.0 ▲	96.7 ●	52.1 ▲	66.5 ▲	29.8 ▲	29.8 ▲	98.1 ●	98.1 ●

Table 1a (continued)
Data completeness for key fields England and Wales

Code	Expected number	Actual Number	% of expected	MDT Completeness (%)	Performance Status Completeness (%)	Stage Completeness (%)	PS & Stage Completeness (%)	Treatment Recorded (%)	Data Completeness Seen by Nurse Specialist (%)	Data Completeness Nurse Specialist present at diagnosis (%)	CT Scan Field Completed (%)	Bronchoscopy Field Completed (%)
N34	**903**	**204**	**23**	**99.0**	**55.4**	**53.4**	**38.2**	**70.1**	**40.7**	**32.8**	**39.7**	**38.7**
RN7	121	81	67	100.0	93.8	77.8	72.8	85.2	100.0	82.7	100.0	97.5
RPA	205	84	41	97.6	38.1	44.0	20.2	45.2	2.4	0.0	0.0	0.0
RVV	374	39	10	100.0	12.8	23.1	5.1	92.3	0.0	0.0	0.0	0.0
RWF	203	0	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
N35	**861**	**550**	**50**	**77.8**	**45.8**	**68.5**	**38.4**	**69.6**	**40.2**	**34.5**	**98.9**	**96.9**
RJD	122	159	130	93.1	89.3	89.9	81.1	64.2	96.2	86.2	100.0	100.0
RJE	345	67	19	86.6	13.4	4.5	0.0	74.6	1.5	1.5	100.0	100.0
RL4	189	176	93	63.6	32.4	97.7	31.8	81.3	4.5	4.5	100.0	100.0
RNA	205	125	61	78.4	34.4	31.2	20.0	57.6	46.4	34.4	95.2	86.4
RWP31	36	17	47	47.1	5.9	100.0	5.9	70.6	0.0	0.0	100.0	100.0
RXW	208	4	2	75.0	0.0	50.0	0.0	75.0	0.0	0.0	100.0	100.0
N36	**2,134**	**2613**	**122**	**99.0**	**85.7**	**85.4**	**76.3**	**94.2**	**83.2**	**64.0**	**88.6**	**71.5**
RE9	134	166	124	99.4	82.5	50.0	43.4	88.6	94.0	74.1	91.0	43.4
RLN	226	274	121	98.9	87.6	89.1	80.7	97.8	97.8	82.5	98.2	97.1
RNL	170	276	162	98.9	77.9	83.3	68.5	86.2	69.2	36.2	93.5	86.2
RR7	132	162	123	98.1	73.5	96.9	72.2	95.7	94.4	61.7	96.3	88.9
RTD	166	294	177	98.6	88.1	88.8	80.3	97.3	97.3	44.9	98.6	97.3
RTF	364	310	85	97.4	69.7	67.4	54.2	92.3	71.9	48.4	98.1	87.7
RTR	270	382	141	99.7	88.0	86.6	78.5	92.7	52.4	51.8	96.1	68.6
RVW	300	322	107	100.0	94.1	94.7	89.8	99.1	96.6	85.1	99.7	99.7
RXP	372	427	115	99.3	97.2	96.3	94.4	95.6	90.4	86.7	46.8	1.6
N37	**1368**	**1089**	**80**	**91.4**	**53.7**	**78.3**	**50.9**	**74.7**	**58.0**	**56.0**	**92.5**	**91.1**
RC1	57	92	161	100.0	89.1	96.7	85.9	84.8	76.1	76.1	98.9	96.7
RCX	112	100	89	87.0	3.0	67.0	3.0	84.0	77.0	75.0	99.0	99.0
RGM	261	18	7	100.0	94.4	94.4	88.9	77.8	94.4	77.8	100.0	94.4
RGN	108	114	106	100.0	50.9	93.9	45.6	70.2	48.2	47.4	98.2	97.4
RGP	131	111	85	82.9	77.5	78.4	72.1	81.1	85.6	73.9	97.3	95.5
RGQ	171	18	11	0.0	0.0	5.6	0.0	0.0	5.6	5.6	100.0	100.0
RGR	52	126	242	100.0	86.5	98.4	85.7	84.9	36.5	35.7	98.4	97.6
RGT	103	159	154	100.0	100.0	94.3	94.3	62.3	45.3	44.7	54.1	50.3
RM1	338	283	84	85.7	2.8	51.6	1.8	82.7	50.2	50.2	100.0	100.0
RQQ	35	68	194	95.6	92.6	95.6	89.7	41.2	83.8	82.4	100.0	97.1
N38	**678**	**778**	**115**	**90.7**	**88.9**	**86.2**	**80.1**	**86.2**	**75.1**	**65.4**	**81.4**	**78.3**
RAJ	192	224	117	97.8	96.0	90.6	87.5	96.0	98.2	98.2	97.3	94.6
RDD	176	207	118	89.9	64.3	59.9	40.6	72.9	48.3	42.0	81.6	72.9
RDE	176	245	139	100.0	100.0	100.0	100.0	95.1	100.0	74.7	99.6	100.0
RQ8	134	101	75	72.3	97.0	97.0	96.0	70.3	17.8	17.8	1.0	0.0
NWW	**433**	**498**	**115**	**88.8**	**60.2**	**63.1**	**41.8**	**69.1**	**88.0**	**0.0***	**64.3**	**42.4**
RT7	111	117	105	88.9	57.3	55.6	35.9	70.1	64.1	0.0*	72.6	47.9
RT8	180	182	101	78.0	61.5	39.6	31.3	64.8	92.9	0.0*	58.8	44.0
RT9	142	199	140	98.5	60.8	88.9	54.8	72.4	97.5	0.0*	64.3	37.7
SEW	**764**	**933**	**122**	**99.6**	**95.8**	**95.5**	**92.0**	**85.3**	**56.2**	**0.0***	**88.0**	**33.9**
RRS	110	136	124	100.0	99.3	97.8	97.1	86.0	95.6	0.0*	97.1	29.4
RVE	102	143	140	100.0	100.0	100.0	100.0	91.6	96.5	0.0*	77.6	27.3
RVF	276	375	136	99.2	96.0	94.4	90.9	77.3	29.3	0.0*	87.2	33.6
RWM	276	279	101	99.6	91.8	93.5	86.7	92.5	52.3	0.0*	90.0	39.8

Table 1a (continued)
Data completeness for key fields England and Wales

Code	Expected number	Actual Number	% of expected	MDT Completeness (%)	Performance Status Completeness (%)	Stage Completeness (%)	PS & Stage Completeness (%)	Treatment Recorded (%)	Data Completeness Seen by Nurse Specialist (%)	Data Completeness Nurse Specialist present at diagnosis (%)	CT Scan Field Completed (%)	Bronchoscopy Field Completed (%)
SWW	**669**	**701**	**105** ●	**98.7** ●	**88.0** ●	**82.7** ●	**75.0** ●	**78.7** ●	**89.2** ●	**0.0***	**90.6** ●	**47.4** ▲
RKU	34	58	171 ●	94.8 ▲	82.8 ●	56.9 ▲	50.0 ▲	82.8 ●	36.2 ▲	0.0*	100.0 ●	79.3 ●
RR6	87	91	105 ●	98.9 ●	86.8 ●	76.9 ●	73.6 ▲	78.0 ●	100.0 ●	0.0*	95.6 ●	56.0 ▲
RVA	133	136	102 ●	100.0 ●	86.0 ●	86.0 ●	75.0 ●	79.4 ●	81.6 ●	0.0*	91.2 ●	36.8 ▲
RVC	243	200	82 ●	99.5 ●	91.5 ●	86.0 ●	79.0 ●	88.0 ●	99.0 ●	0.0*	89.0 ●	33.0 ▲
RVD	172	216	126 ●	98.1 ●	88.0 ●	87.0 ●	78.7 ●	69.0 ▲	94.4 ●	0.0*	87.0 ●	55.1 ▲
Grand Total	**30,094**	**27815**	**92** ●	**92.1** ▲	**69.0** ▲	**78.0** ●	**59.0** ▲	**82.0** ●	**57.3** ▲	**37.8** ▲	**85.2%** ●	**71.2%** ●

The only allowed value for CT and Bronchoscopy on Welsh systems is "Y" thus these fields will only be completed if the intervention is performed.
* Data for 'nurse specialist present at diagnosis' is not recorded in Wales.
** Discussions with trust in progress. Expected number may be inaccurate and therefore achievement underestimated.

Key for Table 1a

For % of Expected (Case ascertainment)

▲ Case ascertainment less than 50%
■ Case ascertainment 50-75%
● Case ascertainment exceeds 75%
◆ Tertiary Trust targets do not apply

For all other data completeness fields

▲ Completeness less than 75% (95% for MDT)
● Completeness exceeds 75% (95% for MDT)
◆ Tertiary Trust targets do not apply

Table 1b
Scotland: Data completeness – key data items

Health Board	Expected number	Actual number	% of expected	MDT completeness (%)	Performance status completeness (%)	Stage completeness (%)	Treatment recorded (%)
SCAN	**1152**	**1109**	**96**	**99.5**	**87.4**	**90.9**	**99.9**
Borders	86	73	85	100.0	90.4	82.2	100.0
D&G	138	102	74	95.1	33.3	77.6	100.0
Fife	277	316	114	100.0	97.8	92.3	100.0
Lothian	651	618	95	100.0	90.1	93.3	99.8
WoSCAN	**2474**	**2081**	**84**	**96.3**	**80.9**	**74.8**	**99.8**
Ayrshire & Arran	323	259	80	100.0	99.2	97.5	100.0
Argyll & Clyde	354	304	86	87.2	39.4	56.9	100.0
Forth Valley	240	175	73	100.0	100.0	84.2	100.0
Lanarkshire	494	426	86	97.7	77.9	80.9	100.0
North Glasgow	652	575	88	96.7	83.8	56.4	99.3
South Glasgow	410	342	83	97.7	93.0	92.9	100.0
NoSCAN	**938**	**868**	**93**	**62.2**	**90.3**	**84.1**	**100.0**
Grampian	384	347	90	82.7	87.6	84.3	100.0
Highland	166	189	114	100.0	100.0	100.0	100.0
Tayside	374	323	86	17.0	88.9	75.0	100.0
Western Isles *	14	9	63	100.0	44.4	55.6	100.0
Total	**4564**	**4058**	**89**	**89.9**	**84.7**	**81.2**	**99.9**

* Most patients with lung cancer from WI are managed by Highland Physicians and some WI cases are included in NHS Highland's data.

Converting data in to service improvement

Case study 2
The East Midland Cancer Network (EMCN)

Following the publication of the previous NLCA reports, clinicians in Leicester and Sheffield noted a marked difference in surgical resection rates between the two areas, which persisted even after adjustment of the figures to account for differing case-mix. Informal discussions suggested that a more in depth analysis and comparison of the two units would be useful.

In 2008, the Leicester hospitals were amalgamated into the EMCN of eight separate hospital trusts and again differences in resection rates were noted across these organisations. Therefore the opportunity to extend the in depth analysis has been taken.

A retrospective analysis of stage I and II non-small cell lung cancer is to be undertaken comparing all eight organisations in the EMCN with the Sheffield unit, by analysing the existing NLCA data from the units, supplemented with extra information on treatment decisions where available. In addition, a proforma has been designed for a prospective data collection, again on early stage patients, which will collect similar data including detailed reasons why individual patients did not have curative treatment.

It is hoped that these analyses will explain the variations seen across the organisations and ensure that all patients receive curative treatment where appropriate.

Table 2a
Process, nursing, imaging and clinical measures

Code	Actual number	% of expected	Discussed at MDT (%)	Histological diagnosis (%)	Patient seen by nurse Specialist (%)	Nurse specialist present at diagnosis (%)	% Having active treatment	% of patients receiving CT before bronchoscopy	% receiving surgery all cases	% receiving radiotherapy
N01	**993**	**100**	**90.3**	**67.7**	**43.7**	**25.1**	**60**	**86.6**	**10.7**	**25.9**
RTX	222	121	89.2	81.1	11.7	0.0	59	72.7	7.7	18.9
RXL	228	94	97.4	81.1	90.4	67.5	69	91.4	15.4	38.6
RXN	242	178	88.0	84.3	80.2	39.3	62	92.1	11.2	26.4
RXR	301	70	87.7	34.2	2.7	0.0	51	85.4	9.0	20.9
N02	**1597**	**75**	**45.7**	**58.8**	**56.4**	**19.4**	**39**	**62.2**	**12.9**	**21.5**
RBT	16	14	6.3	68.8	0.0	0.0	63		31.3	18.8
RBV	0	0								
RJN	53	60	52.8	79.2	84.9	28.3	57	86.1	45.3	17.0
RM2	75	23	12.0	52.0	2.7	0.0	81	33.3	45.3	21.3
RM3	178	132	55.6	44.4	49.4	31.5	31	85.0	11.8	14.6
RM4	83	93	65.1	80.7	85.5	50.6	20	83.1	2.4	15.7
RMC	194	99	53.6	73.2	68.0	22.7	49	2.6	13.9	33.0
RMP	135	104	40.0	82.2	68.1	37.0	60	67.6	13.3	35.6
RRF	302	188	68.9	37.1	92.1	0.7	24	81.6	8.6	12.9
RW3	113	110	46.9	76.1	77.0	45.1	53	69.4	11.5	34.5
RW6	313	60	21.7	43.8	3.8	0.0	25	55.9	4.8	13.7
RWJ	135	129	38.5	83.7	69.6	37.0	50	74.0	15.6	31.9
N03	**1405**	**92**	**90.4**	**60.6**	**46.9**	**11.3**	**52**	**87.4**	**9.3**	**31.5**
RBL	221	186	84.6	67.9	91.4	0.9	48	83.3	8.6	31.2
RBN	161	73	95.7	53.4	71.4	5.6	56	61.1	8.7	31.7
RBQ	195	92	98.5	88.7	0.0	0.0	70	96.0	19.0	35.9
REM	163	50	80.4	30.7	30.1	19.6	52	84.8	4.9	37.4
REN	0	0								
RJR	188	155	92.6	63.8	0.0	0.0	41	0.0	8.5	21.8
RQ6	123	57	91.9	70.7	0.0	0.0	43	92.3	6.5	31.7
RVY	141	172	98.6	58.9	88.7	13.5	52	90.0	9.9	30.5
RWW	213	110	84.5	48.4	78.9	45.5	50	91.7	6.6	32.4
N06	**1669**	**92**	**95.2**	**71.5**	**54.3**	**21.8**	**53**	**74.2**	**11.2**	**25.2**
RAE	209	87	98.6	64.1	76.1	67.0	56	92.8	7.7	34.0
RCB	140	81	93.6	69.3	84.3	13.6	54	88.5	20.0	16.4
RCD	94	103	95.7	89.4	96.8	73.4	51	98.0	9.6	20.2
RCF	74	63	100.0	71.6	6.8	0.0	51	40.0	2.7	2.7
RR8	463	82	93.1	72.1	75.5	0.0	58	64.7	14.1	39.8
RWY	249	102	94.4	80.7	63.5	49.0	60	82.9	10.4	27.3
RXF	440	116	95.9	65.9	5.9	3.0	44	58.7	9.3	12.0
N07	**572**	**76**	**96.3**	**62.8**	**45.5**	**26.6**	**57**	**61.2**	**11.9**	**21.0**
RCC	15	12	73.3	13.3	60.0	53.3	60	60.0	0.0	13.3
RJL	189	84	94.2	57.1	37.6	12.2	46	69.3	3.2	19.6
RWA	368	92	98.4	67.7	48.9	32.9	63	57.7	16.8	22.0
N08	**1146**	**92**	**98.2**	**68.9**	**12.9**	**8.1**	**47**	**84.9**	**11.9**	**12.3**
RFF	119	91	100.0	79.0	1.7	1.7	39	79.4	5.0	12.6
RFR	135	94	98.5	80.0	80.7	46.7	50	80.9	10.4	8.1
RFS	185	106	99.5	52.4	27.6	20.0	39	78.7	15.1	6.5
RHQ	483	101	99.6	70.6	0.2	0.0	55	91.7	16.1	18.4
RP5	343	108	94.8	67.3	0.0	0.0	42	84.0	7.0	8.2

	Number of NSCLC	% of NSCLC having Surgery	Number of PS0-1 NSCLC Stage IIIB or IV	% PS0-1, Stage IIIB or IV NSCLC having chemotherapy	Number of histologically confirmed NSCLC	% of histologically confirmed NSCLC having surgery	Number of patients small cell lung cancer	% small cell receiving chemother-apy	Code
	833	**9.7**	**60**	**55.0**	**516**	**14.5**	**105**	**67.6** ●	N01
	176	4.5	4	75.0	134	4.5	28	75.0 ●	RTX
	177	16.4	30	46.7	134	21.6	40	75.0 ●	RXL
	195	11.8	5	80.0	159	14.5	30	50.0 ▲	RXN
	285	7.4	21	57.1	89	19.1	7	71.4 ●	RXR
	1407	**10.9**	**202**	**26.2**	**752**	**14.0**	**140**	**43.6** ▲	**N02**
	11	36.4			7	28.6	3	66.7 ●	RBT
	◆	◆	◆	◆	◆	◆	◆	◆	RBV
	40	40.0	11	18.2	29	51.7	8	0.0 ▲	RJN
	66 ◆	45.5 ◆	◆	◆	31 ◆	54.8 ◆	5 ◆	100.0 ◆	RM2
	167	11.4	10	30.0	68	17.6	7	42.9 ▲	RM3
	65	1.5	7	0.0	49	2.0	15	26.7 ▲	RM4
	169	8.9	36	27.8	117	10.3	18	44.4 ▲	RMC
	109	10.1	22	54.5	85	12.9	17	76.5 ●	RMP
	282	7.8	69	21.7	93	12.9	15	40.0 ▲	RRF
	91	11.0	8	37.5	64	15.6	21	47.6 ▲	RW3
	294	4.8	1	0.0	118	3.4	16	37.5 ▲	RW6
	113	10.6	38	21.1	91	9.9	15	26.7 ▲	RWJ
	1221	**9.0**	**113**	**55.8**	**687**	**15.4**	**111**	**56.8** ▲	**N03**
	196	8.2	2	100.0	127	12.6	11	36.4 ▲	RBL
	144	9.0	6	50.0	69	18.8	15	80.0 ●	RBN
	161	18.6	27	55.6	139	21.6	26	50.0 ▲	RBQ
	147	4.8	14	64.3	42	16.7	3	33.3 ▲	REM
	◆	◆	◆	◆	◆	◆	◆	◆	REN
	158	7.0	38	42.1	91	12.1	20	60.0 ▲	RJR
	103	5.8	3	66.7	67	9.0	13	38.5 ▲	RQ6
	124	11.3	14	78.6	69	17.4	10	70.0 ●	RVY
	188	6.9	9	55.6	83	13.3	13	69.2 ●	RWW
	1346	**11.5**	**238**	**58.0**	**875**	**15.9**	**241**	**70.5** ●	**N06**
	181	7.7	34	76.5	107	13.1	17	82.4 ●	RAE
	113	16.8	24	58.3	71	25.4	15	46.7 ▲	RCB
	72	12.5	25	52.0	62	12.9	18	77.8 ●	RCD
	56	1.8	13	46.2	36	2.8	15	86.7 ●	RCF
	368	14.9	83	57.8	241	21.6	72	63.9 ●	RR8
	190	9.5	22	72.7	142	12.7	43	74.4 ●	RWY
	366	10.7	37	40.5	216	13.0	61	72.1 ●	RXF
	491	**11.6**	**138**	**48.6**	**283**	**14.1**	**56**	**83.9** ●	**N07**
	12	0.0	6	66.7			2	100.0 ●	RCC
	170	2.9	48	62.5	90	5.6	16	87.5 ●	RJL
	309	16.8	84	39.3	193	18.1	38	81.6 ●	RWA
	1097	**12.8**	**246**	**45.5**	**707**	**16.5**	**115**	**73.0** ●	**N08**
	118	5.1	30	40.0	93	6.5			RFF
	109	10.1	23	60.9	82	13.4	17	82.4 ●	RFR
	168	16.1	42	33.3	81	14.8	12	75.0 ●	RFS
	401	18.2	97	52.6	261	28.0	52	75.0 ●	RHQ
	301	7.6	54	38.9	190	7.9	34	64.7 ●	RP5

Table 2a (continued)
Process, nursing, imaging and clinical measures

Code	Actual number	% of expected	Discussed at MDT (%)	Histological diagnosis (%)	Patient seen by nurse Specialist (%)	Nurse specialist present at diagnosis (%)	% Having active treatment	% of patients receiving CT before bronchoscopy	% receiving surgery all cases	% receiving radiotherapy
N11	**1056**	**99** ●	**95.5** ●	**78.4** ●	**66.0** ●	**39.3** ▲	**56** ●	**85.2**	**13.0** ●	**14.7**
RBK	174	110 ●	93.1 ▲	71.3 ▲	87.4 ●	61.5 ●	48 ▲	83.3	10.3 ●	13.8
RR1	382	95 ●	93.7 ▲	77.0 ●	63.9 ●	44.2 ●	57 ●	85.7	16.8 ●	12.6
RRK	225	92 ●	97.8 ●	82.7 ●	81.8 ●	60.9 ●	62 ●	98.6	12.9 ●	25.8
RXK	273	105 ●	98.5 ●	81.3 ●	42.9 ▲	0.7 ▲	54 ●	77.2	9.2 ▲	8.8
N12	**467**	**113** ●	**93.1** ▲	**86.5** ●	**48.6** ▲	**40.5** ●	**61** ●	**67.8**	**12.0** ●	**25.3**
RJC	47	940 ●	36.2 ▲	93.6 ●	31.9 ▲	25.5 ▲	43 ▲	75.0	6.4 ▲	2.1
RKB	237	95 ●	99.6 ●	87.8 ●	67.1 ●	62.4 ●	65 ●	72.2	12.7 ●	31.2
RLT	115	120 ●	100.0 ●	91.3 ●	0.9 ▲	0.9 ▲	69 ●	50.0	14.8 ●	33.0
RWP01	68	106 ●	98.5 ●	69.1 ▲	76.5 ●	41.2 ●	49 ▲	64.9	8.8 ▲	7.4
N13	**870**	**102** ●	**97.1** ●	**69.7** ▲	**27.1** ▲	**24.8** ▲	**62** ●	**76.7**	**9.7** ▲	**27.8**
RK5	216	127 ●	95.8 ●	66.7 ▲	100.0 ●	98.6 ●	54 ●	66.1	6.5 ▲	21.3
RWD	298	85 ●	95.6 ●	77.5 ●	6.7 ▲	1.0 ▲	64 ●	78.1	6.7 ▲	37.9
RX1	356	107 ●	99.2 ●	64.9 ▲	0.0 ▲	0.0 ▲	65 ●	87.6	14.0 ●	23.3
N14	**451**	**141** ●	**87.1** ▲	**76.5** ●	**58.1** ▲	**33.9** ▲	**68** ●	**77.6**	**12.2** ●	**33.7**
RJF	128	206 ●	89.8 ▲	70.3 ▲	76.6 ●	39.1 ▲	62 ●	77.8	12.5 ●	25.0
RTG	323	126 ●	86.1 ▲	78.9 ●	50.8 ▲	31.9 ▲	71 ●	75.0	12.1 ●	37.2
N15	**813**	**108** ●	**96.6** ●	**72.4** ▲	**24.5** ▲	**9.2** ▲	**65** ●	**88.4**	**21.2** ●	**27.6**
RNQ	179	123 ●	91.6 ▲	68.2 ▲	41.9 ▲	36.9 ▲	58 ●	60.0	21.8 ●	21.2
RNS	141	99 ●	93.6 ▲	68.1 ▲	73.0 ●	6.4 ▲	73 ●	85.0	17.0 ●	34.0
RWE	492	106 ●	99.2 ●	75.2 ●	4.3 ▲	0.0 ▲	65 ●	92.0	22.2 ●	27.8
N20	**540**	**102** ●	**96.1** ●	**73.1** ▲	**50.2** ▲	**33.0** ▲	**42** ▲	**73.5**	**16.7** ●	**21.5**
RC9	141	129 ●	97.9 ●	98.6 ●	53.2 ▲	16.3 ▲	48 ▲	78.1	12.8 ●	24.8
RWG	126	58 ■	93.7 ▲	59.5 ▲	0.0 ▲	0.0 ▲	62 ●		21.4 ●	39.7
RWH	273	133 ●	96.3 ●	66.3 ▲	71.8 ●	56.8 ●	30 ▲	71.0	16.5 ●	11.4
N21	**471**	**58** ■	**96.4** ●	**87.9** ●	**60.1** ●	**55.2** ●	**55** ●	**89.6**	**12.7** ●	**25.1**
RAS	102	97 ●	98.0 ●	94.1 ●	99.0 ●	99.0 ●	61 ●	96.6	10.8 ●	38.2
RC3	58	105 ●	96.6 ●	58.6 ▲	77.6 ●	48.3 ●	57 ●	100.0	5.2 ▲	31.0
RFW	69	125 ●	100.0 ●	89.9 ●	0.0 ▲	0.0 ▲	67 ●	90.7	2.9 ▲	40.6
RQM	52	98 ●	96.2 ●	100.0 ●	0.0 ▲	0.0 ▲	12 ▲		11.5 ●	0.0
RT3 ◆	7 ◆	5 ◆	71.4 ◆	71.4 ◆	0.0 ◆	0.0 ◆	86 ◆	◆	85.7 ◆	0.0 ◆
RV8	40	26 ▲	80.0 ▲	80.0 ●	52.5 ▲	45.0 ●	40 ▲	58.3	7.5 ▲	12.5
RYJ	142	60 ■	100.0 ●	93.0 ●	81.0 ●	78.9 ●	61 ●	93.3	19.7 ●	19.7
N22	**620**	**85** ●	**88.4** ▲	**73.2** ▲	**67.6** ●	**44.0** ●	**49** ▲	**79.7**	**11.9** ●	**18.7**
RAL	93	108 ●	92.5 ▲	72.0 ▲	97.8 ●	89.2 ●	54 ●	86.2	16.1 ●	20.4
RAP	71	85 ●	93.0 ▲	70.4 ▲	93.0 ●	76.1 ●	65 ●	87.5	4.2 ▲	39.4
RKE	80	82 ●	95.0 ●	76.3 ●	83.8 ●	46.3 ●	50 ▲	100.0	10.0 ●	20.0
RQW	78	69 ■	48.7 ▲	47.4 ▲	35.9 ▲	15.4 ▲	28 ▲	77.8	10.3 ●	9.0
RRV	86	62 ■	98.8 ●	100.0 ●	0.0 ▲	0.0 ▲	86 ●	0.0	30.2 ●	17.4
RVL	212	100 ●	92.9 ▲	72.2 ▲	78.8 ●	41.0 ●	33 ▲	72.9	6.6 ▲	14.6
N23	**600**	**77** ●	**74.3** ▲	**56.0** ▲	**76.2** ●	**37.2** ▲	**59** ●	**82.2**	**24.8** ●	**12.2**
RF4	179	53 ■	73.7 ▲	55.9 ▲	56.4 ▲	5.6 ▲	77 ●	88.5	32.4 ●	11.2
RGC	135	117 ●	93.3 ▲	80.0 ●	89.6 ●	61.5 ●	56 ●	69.7	25.9 ●	14.1
RNH	105	91 ●	89.5 ▲	61.9 ▲	82.9 ●	51.4 ●	47 ▲	85.5	11.4 ●	18.1
RNJ	75	68 ■	8.0 ▲	4.0 ▲	74.7 ●	1.3 ▲	72 ●	66.7	36.0 ●	10.7
RQX	104	104 ●	83.7 ▲	56.7 ▲	86.5 ●	72.1 ●	36 ▲	92.1	15.4 ●	6.7

	Number of NSCLC	% of NSCLC having Surgery	Number of PS0-1 NSCLC Stage IIIB or IV	% PS0-1, Stage IIIB or IV NSCLC having chemo-therapy	Number of histologically confirmed NSCLC	% of histologically confirmed NSCLC having surgery	Number of patients small cell lung cancer	% small cell receiving chemother-apy	Code
	877	**12.7**	**183**	**62.3**	**650**	**16.9**	**131**	**62.6** ●	**N11**
	148	10.8	19	73.7	98	16.3	21	66.7 ●	RBK
	310	15.2	72	62.5	222	21.2	48	56.3 ▲	RR1
	185	14.1	62	61.3	146	17.8	34	67.6 ●	RRK
	232	9.1	30	56.7	182	11.0	28	64.3 ●	RXK
	394	**11.9**	**60**	**45.0**	**331**	**13.6**	**42**	**64.3** ●	**N12**
	37	8.1			34	8.8			RJC
	205	12.2	44	45.5	176	13.1	21	71.4 ●	RKB
	92	16.3	14	35.7	82	18.3	17	58.8 ▲	RLT
	60	6.7	2	100.0	39	10.3	4	50.0 ▲	RWP01
	730	**10.0**	**171**	**41.5**	**478**	**13.2**	**102**	**71.6** ●	**N13**
	182	6.6	60	43.3	110	10.9	25	72.0 ●	RK5
	239	7.1	11	72.7	174	9.8	43	67.4 ●	RWD
	309	14.2	100	37.0	194	17.5	34	76.5 ●	RX1
	382	**12.3**	**84**	**66.7**	**280**	**14.6**	**46**	**65.2** ●	**N14**
	104	12.5	33	84.8	69	18.8	16	50.0 ▲	RJF
	278	12.2	51	54.9	211	13.3	30	73.3 ●	RTG
	675	**21.3**	**114**	**44.7**	**453**	**31.8**	**90**	**75.6** ●	**N15**
	159	20.1	23	43.5	103	31.1	10	60.0 ▲	RNQ
	124	17.7	22	54.5	79	27.8	11	81.8 ●	RNS
	391	23.0	69	42.0	270	33.3	69	76.8 ●	RWE
	468	**16.7**	**93**	**24.7**	**324**	**23.8**	**35**	**51.4** ▲	**N20**
	117	12.8	30	36.7	115	13.0	13	46.2 ▲	RC9
	113	20.4	15	46.7	62	35.5	3	100.0 ●	RWG
	238	16.8	48	10.4	147	27.2	19	47.4 ▲	RWH
	377	**12.7**	**70**	**40.0**	**322**	**14.6**	**60**	**51.7** ▲	**N21**
	79	8.9	21	19.0	73	9.6	12	66.7 ●	RAS
	51	5.9	7	57.1	27	11.1	4	50.0 ▲	RC3
	52	3.8	16	62.5	45	4.4	14	42.9 ▲	RFW
	43	11.6	7	0.0	43	11.6	7	0.0 ▲	RQM
	6 ◆	83.3 ◆	1 ◆	0.0 ◆	4 ◆	100.0 ◆	◆	◆	RT3
	30	3.3	4	50.0	23	4.3	3	100.0 ●	RV8
	115	20.9	14	57.1	106	22.6	20	60.0 ▲	RYJ
	537	**13.0**	**107**	**48.6**	**371**	**18.9**	**69**	**68.1** ●	**N22**
	76	19.7	13	76.9	50	30.0	15	60.0 ▲	RAL
	61	4.9	16	50.0	40	7.5	9	100.0 ●	RAP
	67	10.4	8	25.0	48	14.6	10	50.0 ▲	RKE
	73	8.2	8	37.5	32	18.8	3	33.3 ▲	RQW
	76	34.2	27	63.0	76	34.2	9	88.9 ●	RRV
	184	7.1	35	34.3	125	10.4	23	65.2 ●	RVL
	515	**25.2**	**60**	**43.3**	**261**	**20.7**	**53**	**66.0** ●	**N23**
	150	33.3	3	0.0	76	11.8	19	78.9 ●	RF4
	114	25.4	22	45.5	87	25.3	12	66.7 ●	RGC
	85	10.6	25	44.0	48	18.8	12	75.0 ●	RNH
	71	36.6			1	100.0	1	0.0 ▲	RNJ
	94	16.0	10	50.0	49	26.5	8	37.5 ▲	RQX

Table 2a (continued)
Process, nursing, imaging and clinical measures

Code	Actual number	% of expected	Discussed at MDT (%)	Histological diagnosis (%)	Patient seen by nurse Specialist (%)	Nurse specialist present at diagnosis (%)	% Having active treatment	% of patients receiving CT before bronchoscopy	% receiving surgery all cases	% receiving radiotherapy
N24	**726**	**83**	**93.3**	**78.7**	**66.1**	**36.8**	**40**	**84.5**	**7.7**	**14.5**
RG2	171	122	95.9	76.0	76.6	73.7	49	83.6	4.1	9.4
RG3	151	120	97.4	82.1	35.1	23.2	45	92.0	5.3	24.5
RGZ	78	75	65.4	51.3	69.2	34.6	2.6	54.5	0.0	0.0
RJ1**	115	42	96.5	95.7	92.2	67.8	88	88.0	18.3	44.3
RJ2	75	65	90.7	69.3	0.0	0.0	19	0.0	0.0	0.0
RJZ	136	119	100.0	84.6	100.0	0.7	16		14.7	0.7
N25	**466**	**59**	**39.1**	**75.5**	**18.5**	**3.9**	**45**	**66.7**	**8.8**	**14.4**
5LG	2	20	0.0	100.0	0.0	0.0	50		50.0	0.0
RAX	106	67	26.4	81.1	6.6	6.6	41	58.3	3.8	15.1
RJ6	113	86	56.6	63.7	0.0	0.0	43	88.0	3.5	18.6
RJ7	101	42	85.1	96.0	77.2	10.9	71	67.6	24.8	9.9
RPY	0									
RVR	143	58	2.8	66.4	0.0	0.0	31	62.7	4.2	14.0
N26	**1105**	**120**	**89.7**	**70.1**	**41.4**	**33.0**	**60**	**73.7**	**7.0**	**42.7**
RA9	198	127	87.9	68.7	86.9	63.6	62	64.9	8.1	48.5
RBZ	87	102	94.3	71.3	92.0	70.1	59	82.5	9.2	35.6
REF	284	127	90.1	67.3	8.1	6.0	56	93.0	1.4	40.1
RH8	207	104	92.8	82.1	80.2	71.0	74	61.7	19.3	50.7
RK9	328	128	87.2	65.5	4.6	4.0	54	86.2	2.7	38.1
N27	**425**	**106**	**97.9**	**67.3**	**30.1**	**17.6**	**56**	**82.2**	**9.4**	**29.2**
RBD	104	127	99.0	72.1	86.5	54.8	63	93.6	15.4	26.9
RD3	127	85	94.5	70.9	28.3	14.2	59	72.9	8.7	34.6
RDZ	194	114	99.5	62.4	1.0	0.0	49	83.3	6.7	26.8
N28	**792**	**94**	**93.2**	**72.7**	**76.1**	**7.2**	**56**	**71.4**	**4.9**	**25.9**
RA3	77	94	90.9	81.8	77.9	6.5	57	83.9	7.8	11.7
RA4	69	111	87.0	73.9	36.2	27.5	57	76.9	10.1	15.9
RA7	107	59	96.3	63.6	88.8	1.9	61	75.0	6.5	20.6
RBA	175	145	97.1	68.6	79.4	17.7	53	69.7	2.3	40.0
RD1	151	89	98.7	78.8	86.8	0.0	60	87.7	5.3	30.5
RVJ	213	93	87.3	72.8	71.8	0.0	53	51.7	3.3	22.1
N29	**454**	**104**	**93.4**	**87.4**	**66.1**	**25.3**	**68**	**74.3**	**13.7**	**41.2**
RLQ	119	161	96.6	84.0	73.9	39.5	57	70.9	10.9	36.1
RTE	282	116	95.7	87.6	74.5	24.1	73	73.9	13.1	42.9
RWP50	53	45	73.6	94.3	3.8	0.0	64	84.8	22.6	43.4
N30	**1137**	**110**	**93.4**	**77.5**	**19.9**	**9.4**	**53**	**83.7**	**12.8**	**22.2**
RD7	156	139	89.7	84.6	0.0	0.0	35	33.3	10.3	1.3
RD8	79	82	68.4	68.4	36.7	19.0	75	38.1	21.5	31.6
RHW	170	83	98.2	77.6	86.5	45.3	68	96.5	10.0	48.8
RN3	178	158	95.5	67.4	21.9	2.8	35	88.6	7.9	15.7
RTH	353	117	96.9	71.7	2.5	2.3	48	100.0	13.6	16.4
RXQ	201	100	94.0	94.5	1.0	1.0	72	75.0	16.4	27.9

	Number of NSCLC	% of NSCLC having Surgery	Number of PS0-1 NSCLC Stage IIIB or IV	% PS0-1, Stage IIIB or IV NSCLC having chemo-therapy	Number of histologically confirmed NSCLC	% of histologically confirmed NSCLC having surgery	Number of patients small cell lung cancer	% small cell receiving chemother-apy	Code
	614	**9.0**	**113**	**53.1**	**461**	**11.1**	**77**	**58.4** ▲	**N24**
	140	5.0	38	76.3	101	4.0	21	66.7 ●	RG2
	120	6.7	29	41.4	93	7.5	18	72.2 ●	RG3
	70	0.0			32	0.0	7	28.6 ▲	RGZ
	98	20.4	18	88.9	93	21.5	15	86.7 ●	RJ1
	65	0.0	9	33.3	42	0.0	6	50.0 ▲	RJ2
	121	16.5	19	0.0	100	20.0	10	0.0 ▲	RJZ
	407	**6.9**	**18**	**50.0**	**296**	**8.1**	**34**	**61.8** ▲	**N25**
	1	0.0			1	0.0			5LG
	90	4.4			71	5.6	9	55.6 ▲	RAX
	100	3.0	8	37.5	60	5.0	10	40.0 ▲	RJ6
	85	18.8	10	60.0	81	18.5	6	83.3 ●	RJ7
	◆	◆	◆	◆	◆	◆	◆	◆	RPY
	130	3.1			83	2.4	9	77.8 ●	RVR
	903	**6.2**	**139**	**44.6**	**580**	**9.5**	**121**	**70.2** ●	**N26**
	166	8.4	50	46.0	105	13.3	23	87.0 ●	RA9
	78	7.7	6	66.7	53	11.3	6	100.0 ●	RBZ
	239	1.3	21	23.8	149	2.0	24	45.8 ▲	REF
	157	15.9	58	50.0	120	20.0	31	71.0 ●	RH8
	262	3.1	3	33.3	152	5.3	37	70.3 ●	RK9
	341	**7.6**	**88**	**53.4**	**206**	**12.6**	**54**	**79.6** ●	**N27**
	86	16.3	13	69.2	58	24.1	13	76.9 ●	RBD
	100	5.0	25	60.0	63	7.9	18	83.3 ●	RD3
	155	4.5	50	46.0	85	8.2	23	78.3 ●	RDZ
	673	**5.3**	**10**	**80.0**	**458**	**6.6**	**76**	**64.5** ●	**N28**
	62	8.1	4	100.0	48	10.4	12	66.7 ●	RA3
	55	10.9			37	10.8	12	66.7 ●	RA4
	94	6.4			55	5.5	7	71.4 ●	RA7
	140	2.9	6	66.7	86	3.5	23	60.9 ▲	RBA
	130	6.2			98	8.2	13	53.8 ▲	RD1
	192	3.6			134	5.2	9	77.8 ●	RVJ
	379	**12.4**	**101**	**43.6**	**324**	**14.2**	**49**	**51.0** ▲	**N29**
	100	8.0	30	50.0	81	9.9	12	50.0 ▲	RLQ
	235	12.8	68	42.6	202	14.4	32	53.1 ▲	RTE
	44	20.5	3	0.0	41	22.0	5	40.0 ▲	RWP50
	970	**12.2**	**160**	**40.0**	**719**	**16.0**	**98**	**59.2** ▲	**N30**
	150	9.3			127	11.0	1	0.0 ▲	RD7
	67	20.9	2	0.0	43	32.6	8	75.0 ●	RD8
	140	7.9	47	38.3	102	10.8	15	40.0 ▲	RHW
	159	6.3			103	8.7	10	50.0 ▲	RN3
	298	13.8	58	41.4	199	20.1	35	62.9 ●	RTH
	156	17.9	53	41.5	145	18.6	29	65.5 ●	RXQ

Table 2a (continued)
Process, nursing, imaging and clinical measures

Code	Actual number	% of expected	Discussed at MDT (%)	Histological diagnosis (%)	Patient seen by nurse Specialist (%)	Nurse specialist present at diagnosis (%)	% Having active treatment	% of patients receiving CT before bronchoscopy	% receiving surgery all cases	% receiving radiotherapy
N31	**958**	**88**	**93.0**	**81.6**	**32.7**	**21.3**	**68**	**76.3**	**14.9**	**29.6**
RR2/5QT	102	192	98.0	83.3	98.0	95.1	55	52.7	15.7	22.5
RHM	265	59	89.8	79.2	4.9	2.6	81	91.4	31.7	31.3
RHU	249	89	94.4	87.6	0.0	0.0	67		5.6	25.7
RN1	44	47	88.6	77.3	0.0	0.0	68	100.0	6.8	15.9
RN5	59	151	89.8	59.3	71.2	49.2	47	87.0	10.2	22.0
RNZ	98	138	100.0	82.7	75.5	18.4	74	63.6	8.2	41.8
RPR/RYR	141	131	90.8	84.4	59.6	37.6	60	78.4	8.5	37.6
N32	**414**	**77**	**78.0**	**83.8**	**62.1**	**16.7**	**43**	**70.0**	**6.0**	**15.9**
RA2	56	51	66.1	94.6	66.1	0.0	41	73.3	3.6	25.0
RDU	143	123	88.8	80.4	79.7	18.2	54	69.2	8.4	18.2
RTK	111	70	73.0	77.5	54.1	27.0	36	100.0	7.2	6.3
RTP	104	67	75.0	89.4	44.2	12.5	36	66.7	2.9	18.3
N33	**583**	**94**	**96.1**	**68.1**	**63.6**	**15.8**	**48**	**58.9**	**8.1**	**29.3**
RPL	125	89	94.4	69.6	69.6	22.4	44	44.8	1.6	29.6
RXC	242	106	94.2	66.9	90.5	21.9	56	64.2	8.7	36.4
RXH	215	86	99.1	68.4	29.8	4.7	41	62.5	11.2	21.4
N34	**204**	**23**	**97.1**	**76.5**	**40.7**	**27.9**	**60**	**97.5**	**5.4**	**34.8**
RN7	81	67	100.0	93.8	100.0	70.4	77	97.5	13.6	28.4
RPA	84	41	97.6	73.8	2.4	0.0	45	0.0	0.0	45.2
RVV	39	10	89.7	46.2	0.0	0.0	56	0.0	0.0	25.6
RWF	0	0	0	0.0	0.0	0.0	0	0.0	0.0	0.0
N35	**550**	**50**	**72.2**	**84.7**	**35.5**	**20.2**	**50**	**68.1**	**9.5**	**18.9**
RJD	159	130	91.8	83.0	88.7	45.9	42	52.1	10.1	7.5
RJE	67	19	80.6	56.7	1.5	0.0	61	78.9	13.4	14.9
RL4	176	93	54.0	92.0	4.5	2.3	62	80.0	11.4	35.8
RNA	125	61	73.6	92.8	35.2	27.2	36	75.3	0.8	7.2
RWP31	17	47	47.1	88.2	0.0	0.0	65	0.0	17.6	52.9
RXW	4	2	25.0	25.0	0.0	0.0	75		75.0	0.0
N36	**2613**	**122**	**97.4**	**72.6**	**70.9**	**58.7**	**56**	**75.0**	**9.1**	**25.3**
RE9	166	124	98.8	62.7	76.5	70.5	51	67.2	4.2	22.9
RLN	274	121	98.2	74.8	84.7	77.7	47	56.1	6.2	16.1
RNL	276	162	98.6	68.8	55.8	31.9	59	63.5	8.0	43.8
RR7	162	123	95.7	67.9	90.1	50.6	60	83.3	11.1	25.9
RTD	294	177	98.6	77.9	44.9	44.2	59	67.9	11.6	20.1
RTF	310	85	94.5	76.8	65.8	41.3	57	85.4	10.6	16.8
RTR	382	141	97.4	75.4	52.4	51.0	58	88.5	10.7	22.5
RVW	322	107	96.3	68.6	88.8	68.6	61	89.4	13.0	39.1
RXP	427	115	98.4	73.3	86.9	84.1	54	50.0	5.6	21.8
N37	**1089**	**80**	**89.5**	**82.6**	**56.7**	**35.2**	**53**	**81.5**	**9.5**	**23.5**
RC1	92	161	98.9	78.3	76.1	41.3	55	86.3	10.9	31.5
RCX	100	89	73.0	82.0	75.0	13.0	41	41.8	5.0	18.0
RGM	18	7	100.0	94.4	77.8	77.8	56	100.0	33.3	5.6
RGN	114	106	97.4	80.7	48.2	29.8	50	71.4	14.0	12.3
RGP	111	85	82.9	84.7	79.3	39.6	77	96.4	8.1	44.1
RGQ	18	11	0.0	100.0	5.6	0.0	0	0.0	0.0	0.0
RGR	126	242	100.0	75.4	35.7	25.4	56	95.5	11.9	13.5
RGT	159	154	98.1	85.5	44.7	44.7	35	97.1	10.1	11.9
RM1	283	84	85.9	80.2	50.2	29.3	66	79.5	4.6	37.5
RQQ	68	194	95.6	97.1	82.4	79.4	24	100.0	19.1	4.4

Number of NSCLC	% of NSCLC having Surgery	Number of PS0-1 NSCLC Stage IIIB or IV	% PS0-1, Stage IIIB or IV NSCLC having chemo-therapy	Number of histologically confirmed NSCLC	% of histologically confirmed NSCLC having surgery	Number of patients small cell lung cancer	% small cell receiving chemother-apy	Code
791	**14.9**	**170**	**61.2**	**619**	**17.1**	**90**	**75.6** ●	**N31**
87	12.6	41	53.7	70	15.7	7	57.1 ▲	RR2/5QT
221	31.2	39	61.5	168	35.1	16	81.3 ●	RHM
197	6.6			167	6.6	28	75.0 ●	RHU
32	6.3	1	100.0	22	9.1	10	80.0 ●	RN1
51	11.8	14	50.0	27	22.2	6	83.3 ●	RN5
82	7.3	43	69.8	66	9.1	12	83.3 ●	RNZ
121	9.1	32	62.5	99	11.1	11	63.6 ●	RPR/RYR
351	**5.4**	**9**	**11.1**	**286**	**5.9**	**33**	**39.4** ▲	**N32**
47	4.3			44	4.5	5	40.0 ▲	RA2
119	5.9	1	100.0	91	7.7	13	61.5 ▲	RDU
95	7.4	8	0.0	71	8.5	11	18.2 ▲	RTK
90	3.3			80	2.5	4	25.0 ▲	RTP
491	**8.1**	**29**	**62.1**	**312**	**10.9**	**55**	**52.7** ▲	**N33**
100	2.0	1	0.0	63	3.2	13	53.8 ▲	RPL
206	9.2	11	72.7	129	12.4	22	59.1 ▲	RXC
184	10.3	17	58.8	119	13.4	20	45.0 ▲	RXH
182	**4.4**	**27**	**51.9**	**134**	**5.2**	**9**	**66.7** ●	**N34**
66	12.1	21	66.7	61	11.5	9	66.7 ●	RN7
77	0.0	6	0.0	55	0.0	0	0.0 ▲	RPA
39	0.0			18	0.0	0	0.0 ▲	RVV
0	0.0			0	0.0	0	0.0 ▲	RWF
466	**9.0**	**26**	**73.1**	**385**	**10.1**	**53**	**50.9** ▲	**N35**
132	9.1	21	71.4	105	11.4	17	70.6 ●	RJD
59	13.6			30	23.3	7	85.7 ●	RJE
144	10.4			130	11.5	19	26.3 ▲	RL4
112	0.9	5	80.0	104	1.0	9	44.4 ▲	RNA
14	21.4			13	23.1	1	0.0 ▲	RWP31
3	100.0			1	100.0	0	0.0 ▲	RXW
2155	**9.7**	**484**	**57.6**	**1457**	**13.7**	**311**	**64.3** ●	**N36**
137	4.4	17	82.4	77	7.8	14	64.3 ●	RE9
221	7.2	43	58.1	156	9.6	38	57.9 ▲	RLN
230	8.7	60	38.3	144	12.5	39	46.2 ▲	RNL
131	13.7	19	47.4	81	22.2	23	69.6 ●	RR7
247	13.0	53	75.5	183	17.5	29	72.4 ●	RTD
253	10.7	55	60.0	182	12.6	33	69.7 ●	RTF
316	10.8	69	58.0	224	14.3	41	75.6 ●	RTR
261	13.4	68	52.9	164	20.7	42	66.7 ●	RVW
359	6.1	100	59.0	246	8.5	52	61.5 ▲	RXP
882	**10.0**	**105**	**26.7**	**694**	**12.2**	**111**	**51.4** ▲	**N37**
78	10.3	2	50.0	58	13.8	7	71.4 ●	RC1
82	4.9			64	3.1	10	60.0 ▲	RCX
15 ◆	40.0 ◆	4 ◆	25.0 ◆	14 ◆	42.9 ◆	◆	◆	RGM
93	15.1	10	0.0	71	18.3	13	38.5 ▲	RGN
96	9.4	16	75.0	80	11.3	12	100.0 ●	RGP
15	0.0			15	0.0			RGQ
101	11.9	7	71.4	70	17.1	14	50.0 ▲	RGR
128	11.7	48	16.7	105	14.3	17	35.3 ▲	RGT
219	3.7	3	33.3	164	4.9	30	53.3 ▲	RM1
55	21.8	15	0.0	53	22.6	8	0.0 ▲	RQQ

Table 2a (continued)
Process, nursing, imaging and clinical measures

Code	Actual number	% of expected	Discussed at MDT (%)	Histological diagnosis (%)	Patient seen by nurse Specialist (%)	Nurse specialist present at diagnosis (%)	% Having active treatment	% of patients receiving CT before bronchoscopy	% receiving surgery all cases	% receiving radiotherapy
N38	**778**	**115** ●	**88.2** ▲	**74.7** ▲	**65.7** ●	**52.8** ●	**53** ●	**76.3**	**9.3** ▲	**27.8**
RAJ	224	117 ●	91.1 ▲	71.0 ▲	98.2 ●	97.8 ●	44 ▲	81.3	9.8 ▲	15.2
RDD	207	118 ●	88.9 ▲	65.7 ▲	43.0 ▲	32.9 ▲	40 ▲	74.0	10.6 ●	11.1
RDE	245	139 ●	91.8 ▲	80.0 ●	74.7 ●	42.9 ●	71 ●	73.6	10.2 ●	51.0
RQ8	101	75 ●	72.3 ▲	88.1 ●	17.8 ▲	17.8 ▲	60 ●		2.0 ▲	32.7
NWW	**498**	**115** ●	**88.2** ▲	**72.1** ▲	**78.9** ●	**0.0***	**44** ▲	**55.0**	**4.0** ▲	**33.3**
RT7	117	105 ●	86.3 ▲	74.4 ▲	63.2 ●	0.0*	47 ▲	66.1	4.3 ▲	41.0
RT8	182	101 ●	78.0 ▲	69.2 ▲	89.6 ●	0.0*	42 ▲	56.3	0.5 ▲	31.3
RT9	199	140 ●	98.5 ●	73.4 ▲	78.4 ●	0.0*	45 ▲	45.3	7.0 ▲	30.7
SEW	**933**	**122** ●	**97.9** ●	**60.1** ▲	**49.5** ▲	**0.0***	**48** ▲	**76.5**	**4.7** ▲	**37.7**
RRS	136	124 ●	97.8 ●	59.6 ▲	64.0 ●	0.0*	40 ▲	57.5	2.2 ▲	30.1
RVE	143	140 ●	97.2 ●	79.0 ●	87.4 ●	0.0*	64 ●	76.9	4.2 ▲	51.0
RVF	375	136 ●	99.2 ●	50.9 ▲	29.1 ▲	0.0*	43 ▲	84.9	2.4 ▲	37.3
RWM	279	101 ●	96.4 ●	63.1 ▲	50.5 ▲	0.0*	49 ▲	73.6	9.3 ▲	35.1
SWW	**701**	**105** ●	**96.3** ●	**76.5** ●	**80.2** ●	**0.0***	**56** ●	**79.5**	**7.7** ▲	**32.7**
RKU	58	171 ●	94.8 ▲	96.6 ●	19.0 ▲	0.0*	71 ●	87.0	5.2 ▲	22.4
RR6	91	105 ●	91.2 ▲	79.1 ●	96.7 ●	0.0*	58 ●	74.0	7.7 ▲	24.2
RVA	136	102 ●	99.3 ●	66.2 ▲	59.6 ▲	0.0*	48 ▲	86.0	7.4 ▲	27.9
RVC	200	82 ●	98.0 ●	73.0 ▲	96.5 ●	0.0*	52 ●	80.3	9.5 ▲	31.5
RVD	216	126 ●	95.4 ●	79.6 ●	87.5 ●	0.0*	59 ●	75.6	6.9 ▲	43.1
Grand Total	**27,815**	**92** ●	**89.0** ▲	**72.2** ▲	**51.3** ▲	**25.8** ▲	**54** ●	**76**	**10.8** ●	**25.3**
Range Network										
Min		23	39.1	56.0	12.9	3.9	39.3	55.0	4.0	12.2
LQ		80	88.4	68.9	40.7	16.9	47.8	71.4	8.1	21.0
Median		94	93.2	72.9	52.3	25.2	54.0	76.4	9.6	25.3
UQ		108	96.3	78.4	66.0	36.4	59.8	83.7	12.7	29.6
Max		141	98.2	87.9	80.2	58.7	68.1	97.5	24.8	42.7
Range Trust										
Min		0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
LQ		71	84.3	66.6	6.7	0.7	43.9	64.5	5.6	13.8
Median		100	93.6	73.3	63.4	21.0	54.1	77.8	9.7	22.0
UQ		123	97.8	82.1	80.3	45.6	61.6	87.0	13.9	33.0
Max		940	100.0	100.0	100.0	99.0	87.8	100.0	85.7	52.9

* Only allowed value for nursing data on Welsh systems is "Y" for seen by nurse specialist, therefore these fields do not apply to welsh data.
** Discussions with trust in progress. Expected number may be inaccurate and therefore achievement underestimated.

Key for Table 2a

For % of Expected (Case ascertainment)

▲ Case ascertainment less than 50%
■ Case ascertainment 50-75%
● Case ascertainment exceeds 75%
◆ Tertiary Trust. Targets do not apply as most patients are not 'first seen' at tertiary trusts.
These trusts often fully participate in the audit and their performance must not be judged from data shown.

For all other targets

▲ Did not achieve achieved LAP target set in 2008 report
● Achieved LAP target set in 2008***
◆ Tertiary Trust. Targets do not apply as most patients are not 'first seen' at tertiary trusts.
These trusts often fully participate in the audit and their performance must not be judged from data shown.
*** Note that target for Histological diagnosis has been changed to 75%

	Number of NSCLC	% of NSCLC having Surgery	Number of PS0-1 NSCLC Stage IIIB or IV	% PS0-1, Stage IIIB or IV NSCLC having chemo-therapy	Number of histologically confirmed NSCLC	% of histologically confirmed NSCLC having surgery	Number of patients small cell lung cancer	% small cell receiving chemother-apy	Code
	634	**9.5**	**145**	**55.2**	**441**	**12.7**	**84**	**56.0** ▲	**N38**
	183	10.4	45	46.7	119	16.0	27	48.1 ▲	RAJ
	186	9.7	21	47.6	116	13.8	10	20.0 ▲	RDD
	187	10.7	73	63.0	138	14.5	34	73.5 ●	RDE
	77	2.6	5	60.0	67	0.0	13	53.8 ▲	RQ8
	399	**4.8**	**75**	**32.0**	**262**	**7.3**	**77**	**41.6** ▲	**NWW**
	92	4.3	15	20.0	62	6.5	22	13.6 ▲	RT7
	148	0.7	26	46.2	94	1.1	25	56.0 ▲	RT8
	159	8.8	34	26.5	106	13.2	30	50.0 ▲	RT9
	805	**5.0**	**185**	**30.3**	**435**	**8.7**	**95**	**50.5** ▲	**SEW**
	117	1.7	38	34.2	62	3.2	13	38.5 ▲	RRS
	122	4.1	40	35.0	92	5.4	16	43.8 ▲	RVE
	321	2.8	56	25.0	139	5.0	43	34.9 ▲	RVF
	245	9.8	51	29.4	142	16.9	23	91.3 ●	RWM
	573	**9.2**	**162**	**46.9**	**415**	**12.8**	**86**	**59.3** ▲	**SWW**
	50	6.0	9	66.7	48	6.3	5	100.0 ●	RKU
	73	9.6	33	54.5	55	12.7	11	63.6 ●	RR6
	113	8.8	20	45.0	68	14.7	16	56.3 ▲	RVA
	163	11.0	41	46.3	111	16.2	24	54.2 ▲	RVC
	174	8.6	59	40.7	133	11.3	30	56.7 ▲	RVD
	23366	**10.7**	**3,985**	**47.9**	**15774**	**14.2**	**2909**	**62.3** ●	**Grand Total**
									Range Network
		4.4		11.1		5.2		39.4	Min
		8.1		40.0		10.9		51.7	LQ
		9.9		46.9		13.6		62.2	Median
		12.4		55.2		15.9		68.1	UQ
		25.2		80.0		31.8		83.9	Max
									Range Network
		0.0		0.0		0.0		0.0	Min
		5.9		35.0		7.8		45.2	LQ
		9.2		50.0		12.7		61.2	Median
		13.6		62.5		18.6		74.9	UQ
		100.0		100.0		100.0		100.0	Max

Table 2b
Scotland: Process and Clinical Measures

Health Board	Actual number	% of expected	Discussed at MDT (%)	Histological diagnosis (HCR) (%)	% having active treatment	% receiving surgery all cases	Number of patients small cell lung cancer	% small cell receiving chemotherapy
SCAN	**1109**	**96**	**90.1**	**70.7**	**63.5**	**10.1**	**119**	**68.9**
Borders	73	85	86.3	79.5	67.1	12.3	7	71.4
D&G	102	74	94.1	77.4	69.6	13.7	8	87.5
Fife	316	114	84.5	66.2	53.5	8.5	34	55.9
Lothian	618	95	92.7	70.9	67.2	10.0	70	72.9
WoSCAN	**2081**	**84**	**94.3**	**81.6**	**62.1**	**12.5**	**342**	**69.9**
Ayrshire & Arran	259	80	99.2	83.8	61.4	12.0	42	66.7
Argyll & Clyde	304	86	84.2	84.6	59.9	10.2	47	53.2
Forth Valley	175	73	93.7	75.5	57.7	12.0	30	76.7
Lanarkshire	426	86	95.3	88.2	62.9	16.9	79	81.0
North Glasgow	575	88	95.3	80.9	67.3	11.8	91	67.0
South Glasgow	342	83	97.1	73.9	57.0	10.8	53	71.7
NoSCAN	**868**	**93**	**61.2**	**76.1**	**69.8**	**6.6**	**141**	**73.6**
Grampian	347	90	82.7	82.1	79.5	7.8	53	71.7
Highland	189	114	95.8	82.0	68.8	5.3	35	85.7
Tayside	323	86	17.0	66.8	61.0	6.2	53	68.0
Western Isles *	9	63	89.0	56.0	33.0	0.0	0	0.0
Total	**4058**	**89**	**86.1**	**77.5**	**64.1**	**10.6**	**602**	**70.6**

* Most patients with lung cancer from WI are managed by Highland Physicians and some WI cases are included in NHS Highland's data.

Appendices

Appendix 1: Trust identification for England and Wales

N01	Lancashire and South Cumbria
RTX	University Hospitals of Morecombe Bay NHS Trust
RXL	Blackpool, Fylde and Wyre Hospitals NHS Trust
RXN	Lancashire Teaching Hospitals NHS Foundation Trust
RXR	East Lancashire Hospitals NHS Trust

N02	Greater Manchester and Cheshire
RBT	The Mid Cheshire Hospitals NHS Trust
RBV	Christie Hospital NHS Trust
RJN	East Cheshire NHS Trust
RM2	South Manchester University Hospitals NHS Trust
RM3	Salford Royal Hospitals NHS Trust
RM4	Trafford Healthcare NHS Trust
RMC	Bolton Hospitals NHS Trust
RMP	Tameside and Glossop Acute Services NHS
RRF	Wrightington, Wigan and Leigh NHS Trust
RW3	Central Manchester and Manchester Children's University Hospital NHS Trust
RW6	Pennine Acute Hospitals NHS Trust
RWJ	Stockport NHS Foundation Trust

N03	Merseyside and Cheshire
RBL	Wirral University Teaching Hospital NHS
RBN	St Helens and Knowsley Hospitals NHS Trust
RBQ	The Cardiothoracic Centre- Liverpool NHS
REM	Aintree Hospitals NHS Trust
REN	Clatterbridge Centre for Oncology NHS Trust
RJR	Countess of Chester Hospital NHS Foundation Trust
RQ6	Royal Liverpool and Broadgreen University Hospitals NHS Trust
RVY	Southport and Ormskirk Hospital NHS Trust
RWW	North Cheshire Hospitals NHS Trust

N06	Yorkshire Cancer Network
RAE	Bradford Teaching Hospitals NHS Foundation Trust
RCB	York Hospitals NHS Foundation Trust
RCD	Harrogate and District NHS Foundation Trust
RCF	Airedale NHS Trust
RR8	Leeds Teaching Hospitals NHS Trust
RWY	Calderdale and Huddersfield NHS Foundation Trust
RXF	Mid Yorkshire Hospitals NHS Trust

N07	Humber and Yorkshire Coast Cancer Network
RCC	Scarborough and North East Yorkshire Healthcare NHS Trust
RJL	Northern Lincolnshire and Goole Hospital
RWA	Hull and East Yorkshire Hospitals NHS Trust

N08	North Trent
RFF	Barnsley Hospital NHS Foundation Trust
RFR	The Rotherham NHS Foundation Trust
RFS	Chesterfield Royal Hospital NHS Foundation Trust
RHQ	Sheffield Teaching Hospitals NHS Foundation Trust
RP5	Doncaster and Bassetlaw Hospitals NHS Foundation Trust

N11	Pan Birmingham
RBK	Walsall Hospitals NHS Trust
RR1	Heart of England NHS Foundation Trust
RRJ	Royal Orthopaedic Hospital NHS Foundation Trust
RRK	University Hospital Birmingham NHS Foundation Trust
RXK	Sandwell and West Birmingham Hospitals NHS Foundation Trust

N12	Arden
RJC	South Warwickshire General Hospitals NHS
RKB	University Hospitals Coventry and Warwickshire NHS Trust
RLT	George Elliot Hospital NHS Trust
RWP01	Worcestershire Acute Hospitals NHS Trust

N13	Mid Trent Cancer Network
RK5	Sherwood Forest Hospitals NHS Trust
RWD	United Lincolnshire Hospitals NHS Trust
RX1	Nottingham University Hospitals NHS Trust

N14	Derby/Burton Cancer Network
RJF	Burton Hospitals NHS Trust
RTG	Derby Hospitals NHS Foundation Trust

N15	Leicestershire Northampton and Rutland Cancer Network
RNQ	Kettering General Hospital NHS Trust
RNS	Northampton General Hospital NHS Trust
RWE	University Hospitals of Leicester NHS Trust

N20	Mount Vernon Cancer Network
RC9	Luton and Dunstable Hospital NHS Trust
RWG	West Hertfordshire Hospitals NHS Trust
RWH	East and North Hertfordshire NHS Trust

N21	West London Cancer Network
RAS	The Hillingdon Hospital NHS Trust
RC3	Ealing Hospital NHS Trust
RFU	Bedfordshire and Hertfordshire Ambulance and Paramedic Service NHS Trust
RFW	West Middlesex Hospital NHS Trust
RQM	Chelsea and Westmister Healthcare NHS Trust
RT3	Royal Brompton and Harefield NHS Trust
RV8	North West London Hospitals NHS Trust
RYJ	Imperial College Healthcare NHS Trust

N22	North London
RAL	Royal Free Hampstead NHS Trust
RAP	North Middlesex University Hospitals NHS Trust
RKE	The Whittington Hospital NHS Trust
RQW	Princess Alexandra Hospital NHS Trust
RRV	University College London Hospitals NHS Foundation Trust
RVL	Barnet and Chase Farm Hospitals NHS Trust

N23	North East London Cancer Network
RF4	Barking, Havering and Redbridge Hospitals NHS Trust
RGC	Whipps Cross University Hospital NHS Trust
RNH	Newham University Hospital NHS Trust
RNJ	Barts and the London NHS Trust
RQX	Homerton University Hospital NHS Foundation Trust

N24	South East London
RG2	Queen Elizabeth Hospital NHS Trust
RG3	Bromley Hospitals NHS Trust
RGZ	Queen Mary's Sidcup NHS Trust
RJ1	Guy's and St Thomas' NHS Foundation Trust
RJ2	The Lewisham Hospital NHS Trust
RJZ	King's College Hospital NHS Trust

N25	South West London
5LG	Queen Mary's Hospital PCT NHS Trust
RAX	Kingston Hospital NHS Trust
RJ6	Mayday Healthcare NHS Trust
RJ7	St George's Healthcare NHS Trust
RPY	The Royal Marsden NHS Foundation Trust
RVR	Epsom and St Helier University Hospitals NHS Trust

N26	Peninsula
RA9	South Devon Health Care NHS Trust
RBZ	Northern Devon Health Care NHS Trust
REF	Royal Cormwall Hospitals NHS Trust
RH8	Royal Devon and Exeter NHS Foundation Trust
RK9	Plymouth Hospitals NHS Trust

N27	Dorset Cancer Network
RBD	Dorset County Hospital NHS Foundation Trust
RD3	Poole Hospital NHS Trust
RDZ	Royal Bournemouth and Christchurch Hospitals NHS Foundation Trust

N28	Avon Somerset and Wiltshire
RA3	Weston Area Health NHS Trust
RA4	Yeovil District Hospital NHS Foundation Trust
RA7	United Bristol Healthcare NHS Trust
RBA	Taunton and Somerset NHS Trust
RD1	Royal United Hospital Bath NHS Trust
RVJ	North Brsitol NHS Trust

N29	3 Counties Cancer Network
RLQ	Hereford Hospitals NHS Trust
RTE	Gloucestershire Hospitals NHS Foundation Trust
RWP50	Worcestershire Acute Hospitals NHS Trust

N30	Thames Valley
RD7	Heatherwood and Wexam Park Hospitals NHS Trust
RD8	Milton Keynes General Hospital NHS Trust
RHW	Royal Berkshire and Battle Hospitals NHS Trust
RN3	Swindon and Marlborough NHS Trust
RP1	Northamptonshire Healthcare NHS Trust
RTH	Oxford Radcliffe Hospitals NHS Trust
RXQ	Buckinghamshire Hospitals NHS Trust

N31	Central South Coast
RHM	Southampton University Hospitals NHS Trust
RHU	Portsmouth Hospitals NHS Trust
RN1	Winchester and Eastleigh Healthcare NHS Trust
RN5	North Hampshire Hospitals NHS Trust
RNZ	Salisbury Foundation NHS Trust
RPR/RYR	Royal West Sussex NHS Trust
RR2/5QT	Isle of Wight Healthcare NHS Trust

N32	Surrey, West Sussex and Hampshire
RA2	Royal Surrey County Hospital NHS Trust
RDU	Frimley Park Hospital NHS Foundation
RTK	Ashford and St Peter's Hospitals NHS Trust
RTP	Surrey and Sussex Healthcare NHS Trust

N33	Sussex
RPL	Worthing and Southlands Hospital NHS Trust
RXC	East Sussex Hospitals NHS Trust
RXH	Brighton and Sussex University Hospitals NHS Trust

N34	Kent and Medway
RN7	Dartford and Gravesham NHS Trust
RPA	Medway NHS Foundation Trust
RVV	East Kent Hospitals NHS Trust
RWF	Maidstone and Tunbridge Wells NHS Trust

N35	Greater Midlands
RJD	Mid Staffordshire General Hospitals NHS Trust
RJE	University Hospital of North Staffordshire NHS Trust
RL4	The Royal Wolverhampton Hospitals NHS Trust
RNA	Dudley Group of Hospitals NHS Trust
RWP31	Worcestershire Acute Hospitals NHS Trust
RXW	Shrewsbury and Telford Hospital NHS Trust

N36	North of England Cancer Network
RE9	South Tyneside NHS Foundation Trust
RLN	City Hospitals Sunderland NHS Foundation Trust
RNL	North Cumbria Acute Hospitals NHS Trust
RR7	Gateshead Health NHS Foundation Trust
RTD	The Newcastle Upon Tyne Hospitals NHS Trust
RTF	Northumbria Health Care NHS Trust
RTR	South Tees Hospitals NHS Trust
RVW	North Tees and Hartlepool NHS Trust
RXP	County Durham and Darlington Acute Hospitals NHS Trust

N37	Anglia Cancer Network
RC1	Bedford Hospital NHS Trust
RCX	The Queen Elizabeth Hospital King's Lynn NHS Trust
RGM	Papworth Hospital NHS Foundation Trust
RGN	Peterborough and Stamford Hospitals NHS Foundation Trust
RGP	James Paget Healthcare NHS Trust
RGQ	Ipswich Hopsital NHS Trust
RGR	West Suffolk Hospitals NHS Trust
RGT	Cambridge University Hospitals NHS Foundation Trust
RM1	Norfolk and Norwich University Hospital NHS Trust
RQQ	Hinchingbrooke Healthcare NHS Trust

N38	Essex Cancer Network
RAJ	Southend Hospital NHS Trust
RDD	Basildon and Thurrock University Hospitals NHS Foundation Trust
RDE	Essex Rivers Healthcare NHS Trust
RQ8	Mid Essex Hospital Services NHS Trust

SEW	South East Wales Regional Cancer Network
RRS	North Glamorgan NHS Trust
RVE	Pontypridd and Rhondda NHS Trust
RVF	Gwent Healthcare NHS Trust
RWM	Cardiff and Vale NHS Trust

SWW	South West Wales Regional Cancer Network
RKU	Ceredigion and Mid Wales NHS Trust
RR6	Pembrokeshire and Derwyn NHS Trust
RVA	Carmarthenshire NHS Trust
RVC	Swansea NHS Trust
RVD	Bro Morgannwg NHS Trust

NWW	North Wales Regional Cancer Network
RT7	North West Wales NHS Trust
RT8	Conwy and Denbighshire NHS Trust
RT9	North East Wales NHS Trust

Appendix 2: Local Action Plan

Recommendation	Achieved Y/N/P/ NK	Planned Action	Suggested Actions	Suggested Responsibility	Date Planned Actioned	Date issue resolves
Data Completeness and Quality						
The trust participates in this national audit			Contact local Cancer Network for audit advice Contact NCASP Lung Cancer Audit Project Manager (roz.stanley@ic.nhs.uk) Visit www.ic.nhs.uk/services/national-clinical-audit-support-programme-ncasp for information. Obtain read and disseminate the Lung Cancer Audit Annual Report	Cancer Manager / Governance Lead		
Data on all patients diagnosed with either lung cancer or mesothelioma are submitted to the audit			Use MDT meetings to capture all cases discussed, Try to record cases in real time or near real time. Liaise with pathology departments to correlate cases. Work with IT department to set up CSV file upload facility if information is collected on a third party system or identify resources to input data directly	MDT Chair		
All relevant data fields are completed for each patient			Use proforma for data collection at MDT. Identify key person to QA data prior to submission. Data imputers understand clinical implications of data. Map and allocate responsibility along patient pathway. Agree protocols and submission routes for patients that are treated across different organisations	Data Co-ordinator / Cancer Manager / Network Manager		
Actual completeness of at least 80 per cent should be achieved for key data fields including stage and performance status and at least 95 per cent completeness should be achieved for MDT			Refer to the documentation on the National Lung Cancer Audit Website and ensure that key fields are completed for all relevant cases. Assist MDT co-ordinator by chair ensuring that stage, performance status and other key fields are discussed and recorded for each patient	MDT Chair, Data Co-ordinator / Cancer Manager/ Network Manager		
Process of care						
Over 95 per cent of patients submitted to the audit are discussed at an MDT			Liaise with cancer waiting times team to identify lung cancer referrals. Liaise with radiology department to identify all imaging suspicious of lung cancer or mesothelioma. Liaise with pathology department to identify cases	MDT chair, Lung cancer clinical lead		
The Histological Confirmation Rate is at least 75 per cent			Ensure all histological diagnoses are submitted to the audit. Liaise with pathology department to identify cases. Review clinical diagnoses and diagnostics protocols if HCR is below optimum	MDT chair, Lung cancer clinical lead		
The proportion of patients receiving CT prior to bronchoscopy should exceed 90 per cent			Ensure that all CT / bronchoscopy data is submitted to the audit. Review diagnostics protocols if rate is below optimum	MDT chair, Lung cancer clinical lead, Radiologists		
Over 80 per cent of patients are seen by a lung cancer specialist nurse			Review the specialist nurse service, ensuring all nursing posts are staffed and that clear referral pathways exist	MDT chair, Lung cancer clinical lead, specialist nurse		
Over 80 per cent of patients have a lung cancer specialist nurse present at the time of diagnosis			Review the specialist nurse service, allocate extra nursing support alongside lung cancer clinics	MDT chair, Lung cancer clinical lead, specialist nurse		
Clinical outcomes						
Surgical resection rates below the national mean of 11 per cent must be reviewed			Ensure that all surgical resections are submitted to the audit. If data is complete then review treatment policies for early stage lung cancer in patients with good performance status. Ensure that thoracic surgeon attends MDT meetings	MDT chair, Lung cancer clinical lead, thoracic surgeons		
The proportion of patients receiving any active anti-cancer treatment should exceed the national mean of 54 per cent			Ensure that all treatments are submitted to the audit. Review treatment policies for lung cancer patients	MDT chair, Lung cancer clinical lead. MDT members		
The chemotherapy rate for small cell lung cancer should exceed the national mean of 62 per cent			Ensure that all treatments are submitted to the audit. Review treatment policies for small cell lung cancer patients	MDT chair, Lung cancer clinical lead. MDT members		
The chemotherapy rate for patients of PS 0-1 with advanced stage NSCLC (IIIB/IV should exceed the national average of 48 per cent			Ensure that all treatments are submitted to the audit. Review treatment policies for non small cell lung cancer patients with advanced stage	MDT chair, Lung cancer clinical lead. MDT members		

Appendix 3: Glossary

Adenocarcinoma
A cancer of glandular tissue e.g. the mucus-secreting cells that line the airways in lung cancer. This is classified as a type of non-small cell lung cancer. It is less strongly associated with smoking than some other types of lung cancer

Anti-cancer treatment
Treatment to cure or control cancer progression

Asbestos
A fibrous silicate material

Benchmarking
A method of comparing processes and outcomes against standards

Cancer Network
A system within the NHS to organise the integrated care of cancer patients across a region

Case ascertainment
Number of cases recorded as a proportion of those expected

Casemix
A means of classifying patients for comparing quality of care

Casemix Adjusted
Performance and outcome data corrected for various factors including the age, social deprivation, extent of disease and fitness of the populations under study

Chemotherapy
Drugs used in the treatment of cancer

Cytological
From the study of cells

Deprivation
Absence of expected level of social provision

Diagnosis
Confirming the presence of the disease

Histological
From the study of tissues

Interquartile range
The range of a particular variable excluding the highest quarter and lowest quarter of the values recorded

MDT
Multi-disciplinary team

Mesothelioma
Cancer of the lining of the lung caused by asbestos

NCASP
National Clinical Audit Support Programme

Network
See 'Cancer Network'

NLCA
National Lung Cancer Audit

Non-small cell carcinoma
A group of lung cancer including squamous carcinoma and adenocarcinoma

NSCLC
Non-small cell lung cancer

Performance Status
Systematic method of recording the ability of an individual to undertake the tasks of normal daily life compared with that of a normal person

Radiotherapy
Cancer treatment using radiation

SCLC
Small cell lung cancer (small cell carcinoma)

Secondary care
Care provided by a hospital

Small cell carcinoma
Type of neuroendocrine lung cancer strongly associated with smoking

Squamous cell carcinoma
Cancer of cells that cover or line organs of the body e.g. line the tubes of the lung. In lung cancer this is classified as a type of non-small cell lung cancer, it is strongly associated with smoking

Staging / stage
The anatomical extent of a cancer

Surgical resection
An operation to remove abnormal tissues or organs

Thoracic surgeon
Specialist surgeon who operates on the chest and lungs

The NHS Information Centre for health and social care (The NHS IC) is working to make information more relevant and accessible to the public, regulators, health and social care professionals and policy makers, leading to improvements in knowledge and efficiency. The NHS IC is a special NHS health authority that collects analyses and distributes data to reduce the burden on frontline staff, releasing more time for direct care.

Document reference: IC23090809

Need to know more?

T. 0845 300 6016
E. enquiries@ic.nhs.uk
www.ic.nhs.uk

The NHS Information Centre
for health and social care
1 Trevelyan Square
Boar Lane
Leeds
LS1 6AE

Printed on Revive 100 Offset.
A recycled grade containing 100% post consumer waste and manufactured at a mill accredited with ISO14001 environmental management standard.
The pulp used in this product is bleached using a Totally Chlorine Free process (TCF).